The grand escape-how pathogens outsmart the human complement system

The grand escape – how pathogens outsmart the human complement system ☆ A.A. Nowacka a,1 , L. Sordo Vieira b,1 , V. Petr c,1 , B. Fager¨ ang d,e , R. Würzner f,* , M. Ohms a,* a Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany b Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Florida, Gainesville, FL, United States of America c Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic d Department of Immunology, University of Oslo, and Oslo University Hospital, Oslo, Norway e Department of Clinical Immunology, Rigshospitalet, and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark f Institute of Hygiene & Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria ARTICLE INFO Editor: Viviana P. Ferreira Keywords: Immune evasion Complement Pathogen Infection Biomarkers Therapy ABSTRACT Infectious diseases remain a significant cause of mortality and morbidity worldwide. Complement is a critical component in the defense against pathogens and despite their great differences, viruses, bacteria, fungi, and protists have all developed similar mechanisms of evasion from the human complement system. Using examples from four microbial groups (viruses, bacteria, fungi and protists), this review expands on examples of these different mechanisms of evasion. The mechanisms are grouped as (A) avoidance of recognition, (B) avoidance of eradication, (C) avoidance of activation and function, or (D) use of the complement proteins for entry into the host, in accordance with the classification initially proposed in 1999. Furthermore, this review will expand on novel descriptions of complement evasion, for example involving intracellular complement. Taken toge complement evasion is an essential tool used by pathogens not only in a defensive manner, protecting the pathogen from the host, but can also employed in an aggressive manner to aid the invasion of the host. Understanding these mechanisms has already influenced diagnostic and therapeutic tools, including vaccine development, and a further expansion of evasion molecules as biomarkers, vaccines or targets for therapy appears likely in the future. 1. Introduction The complement system is essential for many biological functions, among the most important is host defense against pathogens (Merle et al., 2015a; Merle et al., 2015b). Not only does complement have the ability to kill bacteria directly by damaging their cell membranes (Xie et al., 2020), but it also enhances phagocytosis by opsonization, increases immune cell recruitment by chemotaxis, and regulates the greater immune state of the host (Morgan, 1999). The importance of the complement system can be demonstrated by the large number of evasion strategies that pathogens have developed during their co-evolution with humans. The first comprehensive review reviewing complement evasion mechanisms across all four major kingdoms – viruses, bacteria, fungi and protists – was published in 1999 (Würzner, 1999). Before then, only single groups of microorganisms or even only single pathogens had been looked at. This review from 1999 introduced the concept of dual categorisations. This categorisation classed these mechanisms into two parts, where most pathogens aim to primarily avoid recognition (reviewed in section A), but upon recognition can employ an arsenal to avoid destruction (reviewed in section B-D). However, since 1999 new subclasses and examples of mechanisms have been proposed, especially for the latter, where the invader can ignore any protective measures, and instead employs its armamentarium to invade the host (reviewed in section D2-D3). Furthermore, a new subcategory has only very recently become evident. This category introduces intracellular complement as a target of evasion (reviewed in section B6). ☆ This article is part of a Special issue entitled: ‘Complement System During Infectious Disease’ published in Immunobiology. * Corresponding authors. E-mail addresses: [email protected] (R. Würzner), [email protected] (M. Ohms). 1 Equal contribution: These authors contributed equally to this work. Contents lists available at ScienceDirect Immunobiology journal homepage: www.elsevier.com/locate/imbio https://doi.org/10.1016/j.imbio.2025.153126 Received 17 April 2025; Received in revised form 1 August 2025; Accepted 4 October 2025 Immunobiology 230 (2025) 153126 Available online 24 October 2025 0171-2985/© 2025 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ). This review will focus on different mechanisms though which pathogens can evade complement. We have employed two approaches for our review. One was to study the most recent reviews on this topic and the cited original references therein. The second approach involved conducting a broad literature search in PubMed and Google Scholar using the terms “complement AND evasion”, along with related keywords to ensure comprehensive coverage. We systematically examined both review articles and original research papers, not only to gather established findings but also to identify recurring themes, overlooked mechanisms, or emerging concepts. When a particular aspect offered a novel angle, filled a knowledge gap, or challenged existing understanding, we pursued it in greater depth to gain a more nuanced perspective on the topic. 2. Complement in immune defense against the invader 2.1. Activation of complement Description of complement activation and regulation is out of scope of this review, and we refer the reader to comprehensive papers published elsewhere (Merle et al., 2015a). In brief, the complement system can be activated by three pathways, the classical (CP), lectin (LP) and alternative (AP) pathway. Each pathway has a distinct initiating mechanism that allows recognition of a broad spectrum of structures. The CP is initiated by the binding of of the C1q molecule to prebound immunoglobulins (Ig), IgM, and IgG, or specific pathogenassociated molecular patterns (PAMPs). LP activation occurs through the interaction of mannose-binding lectin (MBL), ficolin-1, -2 or -3, or collectin-11 with carbohydrate moieties displayed on the pathogen surface. The activation of the CP and LP leads to the cleavage of C2 into C2a and C2b, and C4 into C4a and C4b, and the subsequent formation of the C3 convertase C4b2a. The AP is activated by the spontaneous hydrolysis of a labile thioester bond present in the C3 molecule, generating a biologically active conformation, C3(H 2 O). C3(H 2 O) then associates with factor B (FB) and following an interaction with factor D (FD), to form the C3 convertase C3(H 2 O)Bb. All three complement pathways converge at the formation of a C3 convertase, which exists in two main forms: the C3bBb and the C4b2a. The convertases cleaves C3 into C3a and C3b, which binds covalently to surfaces with exposed hydroxyl groups, such as microbial surfaces. Binding of C3b to a surface stabilizes the molecule and increases complement activation through the amplification loop. C3b then joins the enzymatic complexes, forming the C5 convertases (C3bBbC3b or C4b2aC3b). The C5 convertase cleaves the inactive C5 molecule into two active fragments: the anaphylatoxin C5a and the bioactive fragment C5b, and thereby initiates the terminal pathway. C5b sequentially binds to C6, C7, and C8, followed by several C9 molecules. This assembles the membrane attack complex (MAC), also known as C5b-9 or the terminal complement complex (TCC). The C5b-8 complex is embedded into the target membrane, after which C9 molecules polymerize to form a pore, leading to calcium influx and lysis of the pathogen (Merle et al., 2015a). Further details on MAC regulation are discussed below. 3. Complement effector functions Complement is highly capable at preventing infection by invading pathogens and is a central component to both the adaptive and innate immune responses. Complement effector functions include, but are not limited to: •Opsonization of microbes to improve phagocytosis •Chemoattraction of immune cells to sites of infection •Formation of membrane attack complex (MAC) on microbe membranes •Activation of phagocytes to improve immune functions •Connection of the innate and adaptive immune system 3.1. Opsonization Complement-mediated opsonization is a key immune process in which activated fragments of complement proteins – primarily C3b, iC3b, and C4b – bind covalently to microbial surfaces, typically glycoproteins. This deposition effectively "tags" microbes for recognition by the immune system. These complement fragments act as opsonins, facilitating the engagement of complement receptors (CR1, CR3, and CR4) on phagocytic cells such as macrophages and neutrophils. This interaction promotes phagocytosis and results in the clearance of the microbe (Vandendriessche et al., 2021; Lambris et al., 2008). 3.2. Chemoattraction Chemoattraction is the movement of cells in the direction of increasing concentrations of a signaling molecule. This occurs in immunity, in which immune cells are attracted to an area of inflammation through the binding of various signaling molecules, including complement fragments (Fernandez et al., 1978). Complement activation generates the anaphylatoxins, C3a and C5a, which are very potent chemoattractants. Anaphylatoxins bind to the receptors C3aR, C5aR1 and C5aR2 and can induce the migration of leukocytes expressing the C3aR and C5aR1 receptors (Klos et al., 2009). Both C3a and C5a are chemotactic for granulocytes (neutrophils, eosinophils and basophils), monocytes/macrophages and mast cells. In addition, C5a is also chemotactic for dendritic cells (DCs), germinal center B cells and T cells (Klos et al., 2009). 3.3. Mechanisms of MAC The MAC is a crucial component of the immune system’s defense against pathogens, particularly bacteria. MAC formation begins when the complement system is activated on the surfaces of pathogens, resulting in the cleavage of complement component C3 and eventually C5. The C5b forms a stable C5b-6 complex upon binding to C6, which then associates with C7, the limiting molecule for this assembly (Würzner, 2001), to create a firmly attached C5b7 complex on the membrane (Merle et al., 2015a). The subsequent recruitment of C8 causes membrane protrusions and forms a binding site for C9 (Brannen and Sodetz, 2007). Once the first C9 molecule integrates into the C5b–8 complex, additional C9 molecules join, forming a pore that disrupts the bacterial cell membrane and induces lysis (Ramm et al., 1982). The MAC is traditionally known for its ability to lyse gram-negative bacteria. Gram-negative bacteria are particularly vulnerable to MAC lysis due to the outer membrane and their relatively thin peptidoglycan layer. Gram-positive bacteria, on the other hand, have long been considered resistant to MAC-mediated lysis because of their thick peptidoglycan walls. However, this view is becoming increasingly challenged. Recent studies have shown that MAC components can assemble on Gram-positive bacteria at certain sites, and that the effectiveness of this assembly varies among bacterial strains (Berends et al., 2013). In fact, deficiencies in MAC components have been shown to be associated with increased susceptibility to infections, not only by Gramnegative bacteria but also by certain Gram-positive bacteria (Skattum et al., 2011). Some Gram-positive species, such as Streptococcus pyogenes, have evolved mechanisms to evade MAC formation – for example, by producing proteins that block essential steps in the pore formation (Akesson et al., 1996). This demonstrates that the thick peptidoglycan barrier alone is not necessarily sufficient for protection against MAC-induced damage (Akesson et al., 1996). Furthermore, the classical notion that the MAC simply forms pores stretching through bacterial envelopes to cause cell death is still debated; evidence suggests that the mechanism may not involve complete membrane penetration in all cases (Mayer, 1972). Local assembly of the MAC at the bacterial surface is vital for effective bactericidal activity, with membrane-bound C5 convertases A.A. Nowacka et al. Immunobiology 230 (2025) 153126 2 playing a critical role in generating MAC pores that can penetrate the bacterial membranes (Doorduijn et al., 2019). Membrane-bound C5 convertases are crucial for forming bactericidal MAC pores because they cleave C5 directly on the bacterial surface, enabling the unstable C5b fragment to rapidly bind to C6 and C7. This immediate, localized assembly maintains C5b’s active state and supports effective MAC insertion. Preassembled C5b6 formed in solution lacks this coordination and quickly becomes non-functional (Heesterbeek et al., 2019). Recent findings emphasize that for effective bacterial killing, MAC must damage both the outer membrane and inner membrane of gramnegative bacteria, highlighting the intricate nature of bacterial defenses against immune attacks (Doorduijn et al., 2019). Overall, the assembly and function of MAC pores are essential for robust immune responses against a wide range of bacteria. 3.4. Activation of phagocytes The anaphylatoxins bind to a broad spectrum of immune and nonimmune cells. They activate mast cells and basophils to release histamine and they trigger an oxidative burst in macrophages, neutrophils, and eosinophils. Moreover, they regulate vasodilation, increase the permeability of small blood vessels, and induce smooth muscle contractions (Yasuda et al., 2023). Activated neutrophils play a crucial role in the innate immune response, particularly through their interaction with complement factors. Among the complement cleavage products, C5a and C5a des-Arg significantly enhance neutrophil functions, while C3a and C4a show minimal effects. These active fragments stimulate changes in membrane potential, intracellular pH, glucose uptake, and cellular size, leading to increased phagocytosis and reactive oxygen species (ROS) generation (Vandendriessche et al., 2021; Morris et al., 2011; Messerer et al., 2018). C5a also modulates the expression of critical neutrophil activation markers and receptors, including C5aR1, CD62L, CD10, and CD11b (Wohlgemuth et al., 2022). The C5a response is characterized by rapid kinetics, with distinct phases observed for depolarization and alkalization, as well as delayed upregulation of markers like CD11b and CD16 (Wohlgemuth et al., 2022). Concentration-dependent studies of C5a levels indicates its binding to specific receptors, with effective concentrations in the nanomolar range, aligning with inflammation-related levels (Wohlgemuth et al., 2022). Importantly, the activation of neutrophils by C5a does not promote platelet-neutrophil complex formation, suggesting a different mechanism of complement-mediated activation (Wohlgemuth et al., 2022). 3.5. Linkage to the adaptive immune system The complement system has important roles in T cell biology, including the regulation of metabolism, regulation of activation thresholds, receptor expression, and differentiation. For example, simultaneous signaling through pattern recognition receptors and an anaphylatoxin receptor on antigen presenting cells, favors a type 1 T helper response (Th1). The intracellular complement system (complosome) affects cell physiology through direct cross-talk with other intracellular innate sensor systems – so called inflammasomes (Triantafilou et al., 2016; Arbore and Kemper, 2016). This regulates, for example, human Th1 responses by driving the signaling pathways and metabolic reprogramming necessary to induce effector responses (Pavlov et al., 2008; Strainic et al., 2008; Lalli et al., 2008; Heeger et al., 2005; Song, 2012; Liu et al., 2005; Kolev et al., 2015; Hess and Kemper, 2016). Furthermore, complement controls the induction and contraction of T cell responses (Dunkelberger and Song, 2010; Clarke and Tenner, 2014; Kolev et al., 2013). Complement’s regulatory effects can therefore be mediated directly (by modulating the T cell itself) and/or indirectly (by affecting the function of antigen presenting cells) (West et al., 2018). Additionally, a recent study found that the T cell-dependent B cell maturation process is dependent on C3a and C5a signaling. Specifically, germinal center B cells downregulate their surface inhibitors except for CD59, which increases complement activation on their surface while still protecting them from cell lysis (Cumpelik et al., 2021). T celldependent antibody production was reduced in C1q-deficient mice, suggesting the importance of the CP. T cell-independent B cell responses may also be dependent on anaphylatoxin signaling and in particular AP activation (Cumpelik et al., 2023). Of note, an interaction between C3 fragments and complement receptors influences the threshold for B cell activation (Melchers et al., 1985; Kulik et al., 2011; Kov´ acs et al., 2021). 4. Complement regulators The complement system’s powerful functions can harm the host, especially when activated inappropriately during conditions like tissue ischemia and reperfusion. To prevent damage to host cells while effectively targeting foreign materials, mammals have developed various inhibitory proteins to regulate complement activity. C1 inhibitor (C1INH) inactivates C1r and C1s in the CP and MASP-1 and MASP-2 in the LP, thus inhibiting the initiation of these two pathways (Davis et al., 2010). Complement factor H (FH) and complement factor I (FI) are key regulators of the AP, with FI inactivating C3b by forming iC3b in the presence of cofactors such as FH (Roversi et al., 2011). FH also competes with FB for binding to C3b and therefore accelerates the decay of the C3 convertase complex (Ferreira et al., 2010). Membrane cofactor protein (MCP, CD46) acts as a cofactor for FI, facilitating the cleavage of C3b and C4b (Liszewski et al., 1991). Decayaccelerating factor (DAF, CD55) enhances the dissociation of C3 convertases of all three pathways (Hourcade et al., 2002). CR1 acts by removing opsonized immune complexes and has a cofactor activity for FI (Khera and Das, 2009). Thrombomodulin enhances FI-mediated inactivation of C3b and can des-arginate anaphylatoxins, further modulating complement activity (Delvaeye et al., 2009). Vitronectin binds to C5b-7 and C9, preventing their incorporation into membranes and inhibiting polymerization (Preissner et al., 1989). Clusterin binds to C5b-7, C8 and C9 and similarly inhibits polymerization without completely preventing MAC assembly (Tschopp et al., 1993). CD59 is a key regulator of the terminal pathway and blocks the association of C9 with C5b-8 to prevent MAC formation (Farkas et al., 2002). 5. Complosome In recent years, novel insights into complement biology have unveiled the concept of cell-autonomous and intracellular complement, termed the "complosome" (Arbore et al., 2016). This emerging paradigm positions the complosome as a crucial orchestrator of normal cell physiology, influencing essential processes such as mitochondrial activity, glycolysis, oxidative phosphorylation, cell survival, and gene regulation. Its impacts extend beyond immune cells, encompassing nonimmune cells like fibroblasts, as well as endothelial cells (Mahajan et al., 2021) and epithelial cells (Kulkarni et al., 2019). Given these roles, the complosome emerges as a central player in maintaining cell homeostasis and regulating effector responses. The comprehensive review by West and Kemper (West and Kemper, 2023) serves as an excellent resource, providing detailed information on the significance of intracellular complement in cellular functions. Additionally, C3 functions as a sensor for intracellular pathogens, activating cell-intrinsic immunity when a C3-bound pathogen enters the cells (Brock and Parmely, 2017). For instance, C3 bound to Listeria monocytogenes during an infection of intestinal epithelial cells, facilitates the clearance of pathogens by inducing autophagy of the host intestinal epithelial cell (Sorbara et al., 2018). These pieces of evidence demonstrate intracellular roles for C3 when activated C3/C3b is brought into the cytosol by invasive pathogens. Evasion mechanisms related to intracellular complement have not yet been extensively described. A.A. Nowacka et al. Immunobiology 230 (2025) 153126 3 5.1. Avoidance of recognition – disguise 5.1.1. Disruption of antibody-complement interactions Through evolution, pathogens have developed strategies to avoid recognition by the complement system. The ideal solution for pathogens is to avoid immune detection in the first place. Examples of structural barriers that help to disguise pathogens can be found in Table 1. A commonly used feature is molecular mimicry, defined as the sharing of antigenic determinants between the pathogen and host (Fishelson, 1991). The pathogen is thus recognized by the host’s immune system as a self-structure and limited immune response is triggered. Molecular mimicry strategies are also well described causes of autoimmunity (Cusick et al., 2012). For example, the M protein of S. pyogenes elicits the formation of autoantibodies that cross-react with heart myosin which can cause heart damage (Fig. 1A) (Whitton and Feuer, 2004). Antibodies are responsible for many essential functions in the immune system, and as such many pathogens attempt to avoid antibody recognition. There is therefore a strong selection pressure for pathogens to conceal neutralizing epitopes from human antibodies. Common mechanisms of antibody escape include antigenic drift, epitope shielding and immune redirection to dominant but non-protective epitopes (Qerqez et al., 2023). One strategy to evade antibody binding is the expression of highly immunogenic but non-protective decoy epitopes (Hsieh et al., 2021). The primary characteristics of decoy epitopes involve redirecting the humoral response away from important epitopes and promoting the production of non-neutralizing antibodies against non-essential epitopes. Another way to protect neutralizing epitopes is by glycosylation. For instance, the human immunodeficiency virus 1 (HIV-1) envelope is decorated with >25 N-linked glycosylation sites that shields neutralizing epitopes (Kim et al., 2015). Another strategy is the structural blockade of neutralizing epitopes. In severe acute respiratory syndrome coronavirus (SARS-CoV) -1 and -2 the cross-reactive antibody, CR3022, binds a cryptic epitope that is revealed only in a specific conformation of receptor-binding domain (RBD). This way the epitope is concealed from CR3022 until binding to the ACE2 receptor (Yuan et al., 2020). Another mechanism to prevent antibody binding is the expression of Fc receptors or Fc-binding proteins on the pathogen surface. These molecules engage the Fc region of human IgG, which thus blocks antibody-dependent mechanisms. For instance, viruses belonging to the families Herpesviridae and Coronaviridae express receptors that result in the binding of non-specific IgG to the viruses or virus-infected cells, resulting in the steric hindrance of virus-specific immune IgG (Dowler and Veltri, 1984). In some cases an antibody may bind to both the surface epitopes and viral Fc receptors, called antibody bipolar bridging effect, which hinders virus binding. This effectively inhibits most antibody-dependent immune mechanisms (Frank and Friedman, 1989). Some pathogens can also clear antibody-antigen complexes from their surfaces as in the case of alphaherpesvirus pseudorabies virus (PRV) (Favoreel et al., 1999), or parasites such as Trypanosoma (Balber et al., 1979; Frevert and Reinwald, 1990). 5.1.2. Hiding of surface molecules crucial for complement recognition Several pathogens evade complement attack by masking the moieties on their surface that lead to complement activation in the host. Hiding from antibodies is described in section A1. For example, the binding of FH or the prevention of IgM binding to host cell surfaces due to presence of glycosaminoglycans may inhibit complement activity (Dudek et al., 2022). Nontypeable Haemophilus influenzae strains show that a defect in their ability to sialylate LPS leads to less virulent strains. This effect is shown to be FH independent (Figueira et al., 2007) in contrast to the FH mediated effect of sialylated Neisseria gonorrhoeae (Ram et al., 1998). As such, several bacteria have adapted strategies to either synthesize their own sialic acids or utilize host’s machinery to sialylate their surfaces, pretending to be host by molecular mimicry (Fig. 1B) (Vimr et al., 2004). Mutants of the fungal Aspergillus species lacking genes associated with pigmentation, display higher complement deposition on its surface, suggesting a role for melanin in the masking of complement-activating moieties (Speth and Rambach, 2012; Tsai et al., 1997; Tsai et al., 1998). 5.1.3. Capsules as barrier against complement Capsules shield bacteria from recognition and destruction by the host immune response. The capsule of Neisseria meningitidis prevents antibody mediated C1q recruitment to the bacterial surface and inhibits the initiation of the CP (Agarwal et al., 2014). The capsule also masks subTable 1 Structural barriers. Microbial class Species Mechanism Complement target Effect Literature Virus SARS-CoV-1/-2 Epitope masking Likely CP activation “Down” conformation masks epitope from antibody recognition (Yuan et al., 2020) Herpesviridae and Coronaviridae Steric hindrance by binding non-specific antibodies Likely CP activation Steric hindrance by binding non-specific antibodies (Dowler and Veltri, 1984; Frank and Friedman, 1989) HIV-1 Glycosylation of surface Likely CP activation Glycosylation prevents recognition by host’s antibodies, preventing CP activation (Rathore et al., 2017) Fungi A. fumigatus Prevention of complement deposition Complement fragment deposition Melanin might mask complement-activating moieties on the surface of fungus (Speth and Rambach, 2012; Tsai et al., 1997; Tsai et al., 1998) Bacteria Neisseria meningitidis Prevention of C3b deposition and activation of CP Inhibits CP and amplification loop Capsule prevents activation of CP and deposition of C3b, thus preventing both CP and amplification loop. (Agarwal et al., 2014; Roberts, 1996) Neisseria gonorrhea Sialylation of LOS inhibits all activation pathways Inhibits all activation pathways Sialylation of LOS interferes with IgG binding, MBL recognition and represses AP activation through enhanced FH binding and therefore inhibits all three complement pathways (Elkins et al., 1992; Gulati et al., 2002) Streptococcus pyogenes Binding of human proteins to M-protein to avoid complement activation Inhibits all activation pathways M-protein interacts with many human proteins such as FH, IgG Fc domain and albumin to prevent complement deposition and phagocytosis (Whitton and Feuer, 2004) Protist Leishmania spp. Inhibition of MAC mediated killing by surface MAC mediated killing Disruption of glycocalyx inhibits susceptibility to MACmediated killing (Puentes et al., 1950; Sp¨ ath et al., 2003) A.A. Nowacka et al. Immunobiology 230 (2025) 153126 4 capsular targets for C3b deposition, resulting in the interruption of the AP amplification loop (Roberts, 1996). The complex structure of the capsule therefore sterically hinders the binding of C3b molecules to complement receptors on immune cells. Furthermore, some bacteria like Klebsiella pneumonieae, modify their capsule composition by removing rhamnobiose and mannobiose, thereby inhibiting recognition by the LP (Fig. 1C) (Sahly et al., 2009). The lipooligosaccharide (LOS) in N. gonorrhea contains a lacto-Nneotetraose moiety which can be sialylated by the enzyme LOS sialyltransferase (Gilbert et al., 1996). The sialylation of LOS interferes with IgG binding, MBL recognition, and represses AP activation through enhanced FH binding, and therefore inhibits all three complement pathways (Elkins et al., 1992; Gulati et al., 2002). Effective complement activation is crucially dependent on proximity to the pathogen. For instance, IgG-C1q assembly relies on optimal antigen epitope distribution, and proximity is necessary for subsequent CP activation (Diebolder et al., 2014). In addition to inhibiting the binding of C1q and other complement components to the bacterial surface, the elongated O-antigen of Klebsiella pneumoniae inhibits the terminal complement pathway since any deposited C3b is too far away from the membrane to allow further activation or stabilization at the surface (Merino et al., 1992). Acinetobacter baumannii is a Gram-negative bacterium renowned for its exceptional resistance to complement-mediated killing, a key aspect of its serum resistance. A central protective structure is its exopolysaccharide capsule, which is composed of long-chain polysaccharides formed from repeating carbohydrate units, and its synthesis is governed by genes located in the capsule locus. To date, over 128 capsule locus types have been identified, contributing to significant structural and compositional diversity of capsular polysaccharides among A. baumannii strains (Magda et al., 2025). This structural variability plays a critical role in immune evasion. The capsule acts as a physical shield, preventing the effective deposition or insertion of complement components like C3b, C4b, and the MAC into the bacterial surface. Notably, although MAC deposition can occur, especially in some capsule types, A. baumannii often survives despite MAC presence, suggesting incomplete insertion or interference with pore formation (Monem et al., 2020). 5.2. Avoidance of eradication – removal 5.2.1. Removing complement fragments from the pathogen’s surface In case the pathogen is unable to avoid recognition, complement fragments successfully deposit on its surface (Table 2). Many pathogens, however, have acquired the ability to shed these fragments to avoid destruction. A serum-resistant strain of Salmonella (Salmonella minnesota S218) removes the MAC from its surface after addition of C8 and C9 (Fig. 2A) thanks to an inability of the complex to insert into the hydrophobic outer membrane of the pathogen (Joiner et al., 1982). 5.2.2. Protease-dependent mechanisms of complement evasion The neutralization of complement components through degradation into smaller, non-functional fragments represents a key evasion strategy often utilized by bacteria. Two mechanisms for proteolytic cleavage of complement proteins are described. Firstly, the disruption of the complement cascade through pathogen-expressed proteases. Secondly, the acquisition and activation of host-derived plasminogen for indirect plasmin-mediated complement degradation (Ermert et al., 2019). Pathogenic proteases have a wide range of substrates in the complement cascade. The cleavage of immunoglobulin and C1q by e.g., Pseudomonas elastase (PaE) or alkaline protease (PaAP), interferes with the activation of the CP by preventing the formation of ordered IgG Fc hexamers. This, in turn, compromises the structural platform needed for strong Fc–C1q interactions, effectively blocking downstream complement activation (Rooijakkers and Van Strijp, 2007). A CP self-looking antigen self antigen 1) no antibodies are produced -> no classical pathway activation 2) autoantibodies are produced -> autoimmunity Two possible outcomes: C5b-9 B C3b C5b C5b-9 C3b C5b iC3b factor H sialic acid C LP saccharide removal C5b-9 LP Fig. 1. Avoidance of recognition–disguise. (A) Under normal conditions, activation of the CP via antibody-antigen interactions with C1q lead to proper clearance of pathogens. However, some pathogens, such as Streptococcus pyogenes, can present antigens that resemble host antigens, thus disguising themselves as self; a key example is the M protein, a major virulence factor that mimics host antigens through molecular mimicry, particularly in its N-terminal region, enabling the bacteria to evade the host’s immune system by appearing similar to host tissues. (B) Complement activation leads to the potent activation of the membrane attack complex. Sialic acid enhances the binding of FH to host cells (and thus complement inhibition), and thus the decoration of host’s sialic acids either by stealing or de novo synthesis is a common strategy of complement regulation. (C) Modulation of complement-activation molecules from pathogen’s surface is another common mechanism to evade complement attack. For example, K. pneumonia lacking mannose-poor O antigens are less susceptible to killing by polymorphonuclear leukocytes. A.A. Nowacka et al. Immunobiology 230 (2025) 153126 5 Many pathogens degrade C3 as a central component of the complement cascade, circumventing the downstream complement functions like opsonization, phagocytosis, signaling through anaphylatoxin receptors and MAC formation. S. pyogenes exotoxin B (SpeB), a cysteine protease and an important virulence factor in Group A Streptococcus (GAS) infections, degrades serum C3 and enables GAS to resist complement damage, opsonization and prevents phagocytosis (Kuo et al., 2008). The cleavage of C3 by the autotransporter NaIP from Neisseria meningitidis occurs four amino acids upstream from the natural C3 cleavage site and produces shorter C3a-like and longer C3b-like fragments (Del Tordello et al., 2014). The C3b-like fragment has higher affinity for degradation by host complement regulators, FH and FI, and does not lead to C3b deposition on the bacterial surface (Del Tordello et al., 2014). Staphylococcus aureus relies on a whole arsenal of virulence factors to escape the host immune response including the six serine-protease-like proteins, SplA to SplF. Notably, SplB functions as a potent and broadspectrum protease that targets multiple complement components, effectively compromising the integrity of the entire complement system (Dasari et al., 2022). It inactivates C3, C4 and activation fragments C3b and C4b by preferentially cleaving their alpha chains. Moreover, it can cleave the components of the terminal complement pathway, C5, C6, C7, C8 and C9 (Dasari et al., 2022). Thus, through the expression of one multifunctional protease S. aureus escapes two major functions of the complement system, the C3b-mediated phagocytosis as well as the MAC deposition on the bacterial surface. Not only bacteria evade complement activation through protease expression. The presence of the complement-degrading fungal serine protease Alp1 was shown in the supernatant of Aspergillus fumigatus cultures in cerebrospinal fluid (CSF) (Rambach et al., 2010). Alp1 has a cleavage affinity for the complement proteins C1q, C3, C4, C5, MBL, and FD (Rambach et al., 2010; Behnsen et al., 2010). Trypanosoma cruzi displays a surface complement regulatory protein (CRP) which binds C3b. It is believed that the CRP-C3b complex is then cleaved by the parasitic cysteine protease reducing both C3 convertase formation and C3b opsonization on the pathogen’s surface (Fig. 2B) (Norris, 1996a; Norris, 1996b). 5.2.3. Use of enzymes of the coagulation cascade for evasion In addition to host-derived complement regulators, pathogens can also hijack host proteases to attenuate complement activation, e.g. plasminogen via plasminogen binding proteins. Once bound to such a microbial receptor, plasminogen becomes accessible and can be activated by either human or microbial activators resulting into its active form, plasmin. Plasmin suppresses complement at the level of C3 and C5, by cleaving these central proteins (Fig. 2C) (Potempa and Potempa, 2012). Plasminogen is, as a component of the coagulation system, abundant and thus omnipresent in the circulation, turning it into an easily accessible target for many human pathogens including: Haemophilus influenzae (Barthel et al., 2012), Pseudomonas aeruginosa (Kunert et al., 2007), Borrelia burgdorferi (Brissette et al., 2009), Streptococcus pneumoniae (Bergmann et al., 2004), S. aureus (Koch et al., 2012), and Candida albicans (Luo et al., 2009). Another well studied example for plasminogen acquisition and activation is Leptospira. At least eight proteins act as plasminogen-binding receptors of Leptospira, including the major outer membrane protein, LipL32 (Vieira et al., 2010). Activation of plasminogen either happens through microbial proteins on the surface of Leptospira or host-derived activators, like urokinase-type Table 2 Shedding or destruction. Microbial class Species Mechanism Complement target Effect Literature Virus Alphaherpesvirus Pseudorabies virus, Clearance of antibody-antigen complex CP activation Clearance of antibody-antigen complex prevents recognition by CP (Favoreel et al., 1999) Flavivirus Promoting cleavage of C4 C4 NS1 promotes cleavage of C4 into C4b, and also promotes the recruitment of C4BP, inactivating C4. (Avirutnan et al., 1950) RSV Rhinovirus, Polio 2 Virus C3 degrading proteases C3 C3 degrading proteases inhibits intracellular opsonization by complement. (Tam et al., 2014) Bacteria K. pneumoniae Removal of sugar moieties LP recognition Removal of sugar moieties on capsule prevents recognition by LP (Sahly et al., 2009) Pseudomonas spp. Pathogen proteases cleaving complement C1q Cleavage of C1q targets the CP (Rooijakkers and Van Strijp, 2007) Salmonella spp. Shedding complement from the pathogen’s surface Assembling MAC Complement activation impaired (Joiner et al., 1982) Streptococcus pyogenes Degradation of C3 by protease Streptococcal pyrogenic exotoxin B C3 Impairs opsonization and all complement pathways (Kuo et al., 2008) Streptococcus pyogenes Release of complement-degradating proteins from pathogen surface C5a Releases a C5a peptidase, inhibiting chemotactic potential of C5a. (Berge and Bj¨ orck, 1995) Neisseria meningitidis NalP cleaves C3 C3 and downstream opsonization Impairs opsonization and the anaphylatoxin effects of C3a. (Del Tordello et al., 2014) Staphylococcus aureus Serine protease-like protein B (SplB) cleaves C3-C9, and FB and activation fragments of C3 and C4 C3-C9, FB and activation fragments of C3 and C4. Blocks all complement pathways (Dasari et al., 2022) Fungus Aspergillus fumigatus Alp1 degrades C1q, C3, C4, C5, MBL, FD C1q, C3, C4, C5, MBL, FD Reduced opsonization and phagoyctosis. (Rambach et al., 2010; Behnsen et al., 2010) Protist Trypanosoma spp. Clearance of antibody-antigen complex CP activation Clearance of antibody-antigen complex prevents recognition by CP (Balber et al., 1979; Frevert and Reinwald, 1990) Cleavage of C3b Removal of C3b from surface Binding of C3b to complement regulator y protein renders it susceptible to cleavage (Norris, 1996b) A.A. Nowacka et al. Immunobiology 230 (2025) 153126 6 plasminogen activator (uPA) (Vieira et al., 2009). The bacteriaassociated plasmin prevents IgG and C3b deposition on the leptospiral surface through cleavage and increases survival upon infection. The malaria parasite, Plasmodium falciparum, also binds human plasminogen which then gets converted to plasmin, and leads to the cleavage of C3b, ultimately inhibiting MAC activity (Reiss et al., 2021). 5.2.4. Chemical modifications of complement proteins In addition to protease or peptidase cleavage, some pathogens have also acquired the ability to inhibit complement by chemical modifications. For example, the Leishmanial enzyme LPK-1, an outward facing surface protein kinase, which is rare in eukaryotic cells, can cause C3 and C5 phosphorylation, which is believed to inhibit cleavage of these proteins (Fig. 2D) (Hermoso et al., 1991). 5.2.5. Distracting complement activation off the microbe A secreted and then extracellular cysteine protease (SCP) of S. pyogenes leads to the activation of complement in the surroundings of S. pyogenes, but decreased complement deposition on the surface of the bacteria (Berge et al., 1997). As a secondary mechanism of S. pyogenes, SCP also releases a C5a peptidase that diminishes the effects of complement activation in the vicinity of the bacteria (Berge and Bj¨ orck, 1995). This is similar to the effects of pneumolysin from S. pneumoniae which also causes complement activation away from the surface of the microbe (Fig. 2E) (Mitchell and Andrew, 1997). In one study, galactosaminogalactan (GAG), a molecule secreted by Aspergillus during co-culture with human platelets, was shown to induce complement activation and deposition on the platelets, thereby reducing their viability. However, it remains unclear whether this process also led to reduced complement deposition on the Aspergillus itself, as this aspect was not addressed in the study (Deshmukh et al., 2020). Platelet loss can potentially lead to a higher hemorrhage and consequently to more access to free heme for the fungus, a key source of iron. Trypanosoma brucei evades host immunity through the rapid internalization and recycling of its dense coat of variant surface glycoproteins (VSG). This high turnover is crucial for the removal of host immune effectors, including antibodies and other covalently bound complement proteins. These proteins are targeted for degradation and thus prevented C3b C3b C3b C3b C3b C3b iC3b C3b C3b C3b iC3b iC3b iC3b iC3b iC3b iC3b iC3b C3b C3b C3b iC3b iC3b iC3b C3b C3b C3b iC3b iC3b response response diminished C3b iC3b complement receptors C3b iC3b C3b iC3b C3b iC3b complement depletion C1q Streptococcus pneumoniae pneumolysin CP C5b-9 plasminogen plasminogen plasmin C3, C5 9 9 -9 -9 9 9 9 C3b C5b C3 C5 C3-convertase C5-convertase P C3 C5 Pphosphorylated forms are resistant to cleavage P C5b-9 C3b C5b C5b-9 C6, C7 C5b-7 C8, C9 C3b C5b C6, C7 C5b-7 C8, C9 C5b-9 C3b C5b C5b-9 C3b Trp-CRP AB CD EF C 5 b - 9 Trp-CP Trp-CP tPA uPa Fig. 2. Avoidance of eradication–removal. (A) Serum-resistant Salmonella minnesota S218 sheds the MAC from its surface after addition of C8 and C9 as the nascent complex cannot insert into the hydrophobic outer membrane of the pathogen. (B) Trypanosoma cruzi displays CRP which binds C3b there and the CRP-C3b complex is then cleaved by the parasitic cysteine protease CP downmodulating complement activation. (C) Pathogens can hijack host proteases to attenuate complement activation, e.g. plasminogen via parasitic plasminogen binding proteins. Once bound, plasminogen can be activated by either human or microbial activators to its active form, plasmin, which cleaves C3 and C5 via the action of C5 and C3 convertases. (D) Leishmanial surface protein kinase LPK-1 can phosphorylate C3 and C5, thereby inhibiting their cleavage. (E) S. pneumoniae pneumolysin is released and then causes complement activation away from the surface of the pathogen. (F) Complement coated non-enveloped viruses induce intracellular complement sensing leading to inflammation, whereas enveloped viruses, such as RSV, leave the C3b on the outside of the cell when engulfed, resulting in a diminished complement activation. A.A. Nowacka et al. Immunobiology 230 (2025) 153126 7 from recycling back to the surface. In doing so, the parasite minimizes effective opsonization and complement-mediated lysis, thereby avoiding recognition and clearance by macrophages during chronic infection. In addition, the constant shedding of VSG molecules acts as a decoy mechanism, diverting complement activation away from the parasite and leading to ineffective complement consumption and potential hypocomplementemia (Onyilagha and Uzonna, 2019). 5.2.6. Evading attack of intracellular complement The mechanism of intracellular complement sensing is now recognized as a potent anti-microbial mechanism in mammalian cells to sense pathogens that have been tagged by complement and internalized (Tam et al., 2014). Enveloped viruses, such as respiratory syncytial virus (RSV), are believed to be resistant to intracellular complement sensing since their opsonization in the extracellular space should occur on the Table 3 Recruitment for protection. Microbial class Species Mechanism Complement target Effect Literature Virus Sindbis Virus Sialic acid on pathogen surface FH recruitment Quantity of sialic acid and subsequent recruitment of FH influence AP activity (Hirsch et al., 1983; Hirsch et al., 1950) HIV-1 CD46, CD55 and CD59 incorporated into HIV-1 particles and function to protect virions from complement-mediated destruction CD46, CD55, CD59 Protects from complement mediated destruction by complement-regulating mechanisms (Montefiori et al., 1994; Saifuddin et al., 1995) Human Cytomegalovirus Upregulation of CD46 and CD55 on the infected cells CD46, CD55 Inhibition of all pathways (Spiller et al., 1996) Vaccinia virus Incorporation of CD46, CD55, and CD59 into the outer envelope CD46, CD55, CD59 Inhibition of all pathways (Vanderplasschen et al., 1998) Bacteria Neisseria gonorrhoeae Glycosylation of pathogen surface FH Glycosylation enhances binding of FH to pathogen surface, resulting on inhibition of complement by FH (Ram et al., 1998; Vimr et al., 2004) Pseudomonas aeruginosa, Mycoplasma hyopneumoniae Binding of host’ FH and/or plasminogen FH Binding of FH and plasminogen leads C3b degradation and cleavage of plasminogen substrates (Kunert et al., 2007; Yu et al., 2020) Borrelia burgdorferi Binding of FH, FHL-1, plasminogen FH, FHL-1, plasminogen, C7, C9 Enhances FH-mediated C3 inactivation, inhibits MAC, and degrades plasminogen substrates (Hart et al., 2018; Siegel et al., 2008; Hartmann et al., 2006) Binding of FH, FH-L1 with complement regulator acquiring surface proteins FH, FHL-1 Inhibition of C3 activation & C3 convertase formation, termination of the assembly and finally the integration of the MAC into the bacterial membrane (Locke, 2019) Acinetobacter baumannii Recruitment of FI leads to formation of complex and degradation of C3b and C4b C3, C3b, C4b, C5, FB, FD & esp. FI Inhibition of all three complement pathways. (Ries et al., 2022) Leptospira sp. Once bound to the leptospiral surface, FH and C4BP retain cofactor activity of FI in the cleavage of C3b and C4b FH, FH-like-1, C4BP, Vitronectin Binding of vitronectin suppresses polymerization of C9 (Fraga et al., 2016) Fungus Candida albicans, Aspergillus fumigatus Recruitment of FH and other complement regulators to surface FH, FHL-1, C4BP, plasminogen Avoids activation of complement (Kenno et al., 2018; Dasari et al., 2019; Meri et al., 2002; Luo et al., 2011) Protist Trypanosoma cruzi Transfer of host cell sialic acids Promotes negatively charged surface inhibiting AP. Avoids activation of complementmediated lysis and enhances intracellular invasion (Tomlinson et al., 1950; Weatherly et al., 2016; DcRubin and Schenkman, 2012) Plasmodium spp. Recruitment of C1-INH to the surface PfMSP3.1 protein C1-INH Inhibition of activating proteases of the complement cascade C1s, MASP1, and MASP2 (Kennedy et al., 1950) Plasmodium falciparum Glideosome-associated protein 50 (GAP50) binds to FH FH, Binds FH and uses surface-bound FH to inactivate C3b (Schmidt et al., 2015; Simon et al., 2013) Inhibition of terminal complement pathway by CD59 recruitment PfPIG-M Prevention of MAC formation on pathogen-infected red blood cells (Kiyuka et al., 2020; Rashidi et al., 2022; Wiesner et al., 1997; Kim and Hong, 2007) Inhibition of C3-convertases by C4BP recruitment Circumsporozoite protein (CSP) (Khattab et al., 2022) Trichomonas vaginalis Inhibition of terminal complement pathway by CD59 recruitment unknown Prevention of MAC formation and pathogen lysis (Ib´ a˜ nez-Escribano et al., 2015) Leishmania species C4bBP receptor Acceleration of C3-convertases decay (Pereira-Filho et al., 2023) Entamoeba histolytica Recruitment of CD46, CD55, and CD59 by trogocytosis Inhibition of all three pathways (Miller et al., 2022) Toxoplasma gondii Recruitment of C4BP, FH to the surface to inactivate surfacebound C3 and limit formation of the MAC FH, C3b, C4BP Blockade of AP amplifies complement activation & killing of T. gondii (Rashidi et al., 2022; Sikorski et al., 2020; Sikorski et al., 2021) A.A. Nowacka et al. Immunobiology 230 (2025) 153126 8 lipid membrane and thus be left behind in the process of membrane fusion (Fig. 2F) (Tam et al., 2014). Another important mechanism to evade intracellular complement sensing is by the expression of C3 degrading proteases by viruses, such as human rhinovirus or poliovirus 2 (Tam et al., 2014). This then downregulates opsonization or neutralization in the extracellular space and may also prevent intracellular sensing once internalized. This appears to be a common evasion strategy among viruses. 5.3. Avoidance of activation and function – Inhibition 5.3.1. Interruption of complement activation The most direct strategy to abrogate complement activation lies in the interruption of the specific protein-protein interactions that orchestrate the complement cascade. For this purpose, many pathogens express proteins that act as complement inhibitors that can either block, catch or destabilize complement (Table 3). A viral example of the suppression of complement activation through C1q binding is the coat protein of human Astrovirus type 1 (HAstV-1) through the replacement of the C1rC1s tetramer (Bonaparte et al., 2008; Hair et al., 2010). Moreover, the HAstV-1 coat protein can bind MBL and therefore stops LP activation. Since the C3 convertase plays a central role in the cascade, it has become an obvious target for pathogenic invaders. Properdin (FP), is a positive AP regulator, is blocked from binding to bacterial surface by LPS (Ermert et al., 2019). The glycoprotein C (gC) of Herpes simplex virus 1 (HSV-1) impedes complement from two sites: one gC domain blocks FP and C5 binding to C3b, and another disables C3 and its fragments (Fig. 3A) (Fries et al., 1950; Hung et al., 1994; Kostavasili et al., 1950). Inhibition of the LP is another target for human pathogens. For example, T. cruzi utilizes Nand O-glycosylated molecules on its surface to bind Land H-ficolins, and MBL and thereby impedes MASP-1 and 2-induced C2 and C4 cleavage (Kahn et al., 1996; Cestari and Ramirez, 2010; Ribeiro et al., 2015). Additionally, the T. cruzi CRP binds the collagenous part of Lficolin and inhibits the LP initiation (Sosoniuk et al., 2014). 5.3.2. Interference with anaphylatoxin generation and MAC assembly Interference with MAC formation represents the final opportunity for pathogens to evade complement-mediated lysis, and numerous microorganisms have evolved mechanisms to exploit this stage of the cascade. CspA is a surface-exposed protein of B. burgdorferi that inhibits the terminal complement pathway by directly binding to the complement components C7 and C9, thereby blocking MAC formation on the bacterial surface and in solution (Hallstr¨ om et al., 2013). The leptospiral surface protein LcpA binds to the human serum component vitronectin and thereby suppresses polymerization of C9 (Fraga et al., 2016). The Staphylococcus super antigen-like 7 (SSL-7) protein prevents MAC formation at an earlier step: it binds C5 and blocks its interaction with the C5 convertase leading to a lack of C5b (Bestebroer et al., 2010). Inactivating mechanisms of the anaphylatoxins are also present in bacteria, such as Streptococcus through ScpA (Lynskey et al., 2017). The protein chemotaxis inhibitory protein of S. aureus (CHIPS) inhibits chemotaxis of neutrophils and monocytes towards C5a by binding directly to C5aR1, thus preventing the chemotactic activity of C5a (Postma et al., 2004; de Haas et al., 2004). MAC formation on virus-infected cells can lower the viral load. For instance, Zika virus inhibits MAC formation and complement-mediated lysis by binding terminal complement components to its viral E protein (Malekshahi et al., 2020). The secreted protein Pra1 from C. albicans can bind C3a (as well as other C3 fragments) and prevent effector mechanisms (Luo et al., 2018). The extracellular cysteine proteinase of the protozoa Entamoeba histolytica degrades the anaphylatoxins C3a and C5a, thus preventing the immunomodulatory effects of the anaphylatoxins (Fig. 3B) (Reed et al., 1950). 5.4. Employment – hijacking and mimicry of host complement components 5.4.1. Employment of complement regulators for microbial protection For the hosts, complement regulators are crucial for preventing damage of host tissue, hijacking of complement regulator functions are widely used as a mechanism of evasion (Table 4). Moreover, as many regulators share structural features, pathogens can synthesize a small arsenal to recruit various regulators, thus providing a low-cost solution to evading host’ complement (Lambris et al., 2008). One particularly common and shared mechanism is the employment of FH, FH like protein-1 and FH-related proteins to inhibit complement activation early in the cascade (Moore et al., 2021). An alternative strategy to utilizing the host’ complement regulator arsenal is to encode proteins that mimic the function of host’ proteins. Mimicry of host molecules can be used in a protective way, an aggressive C3b C5bC3 C3a C5a C3aR C5aR1 protease A B C3b C5b gC protein infected host cell C5 b -9 Fig. 3. Avoidance of activation and function–inhibition. highly specific protein-protein interactions are the key feature of the complement cascade, and their abrogation is a common feature of pathogen evasion strategies. (A) A prominent example for this evasion strategy is the mature Herpes simplex virus (HSV) glycoprotein C (gC) that inhibits the activation of the complement cascade by binding C3b and by blocking binding of properdin and C5 to C3b, thereby interfering with the generation of the membrane attack complex (MAC) and the lysis of infected host cells. (B) The pathogen-derived complement-active proteases from Entamoeba histolytica and streptococci bacteria can degrade the anaphylatoxins C3a and C5a consequently blocking the activation of anaphylatoxin receptors C5aR and C3aR and their downstream assigned effector functions. A.A. Nowacka et al. Immunobiology 230 (2025) 153126 9 Ekdahl, K.N., Persson, B., Mohlin, C., Sandholm, K., Skattum, L., Nilsson, B., 2018. Interpretation of serological complement biomarkers in disease. Front. Immunol. 9, 2237. https://doi.org/10.3389/fimmu.2018.02237. Elkins, C., Carbonetti, N.H., Varela, V.A., Stirewalt, D., Klapper, D.G., Sparling, P.F., 1992. Antibodies to N -terminal peptides of gonococcal porin are bactericidal when gonococcal lipopolysaccharide is not sialylated. Mol. Microbiol. 6 (18), 2617–2628. https://doi.org/10.1111/j.1365-2958.1992.tb01439.x. Engstler, M., Pfohl, T., Herminghaus, S., et al., 2007. Hydrodynamic flow-mediated protein sorting on the cell surface of trypanosomes. Cell 131 (3), 505–515. https:// doi.org/10.1016/j.cell.2007.08.046. Eriksson, O., Hultstr¨ om, M., Persson, B., et al., 2020. Mannose-binding lectin is associated with thrombosis and coagulopathy in critically Ill COVID-19 patients. Thromb. Haemost. 120 (12), 1720–1724. https://doi.org/10.1055/s-0040-1715835. Ermert, D., Ram, S., Laabei, M., 2019. The hijackers guide to escaping complement: Lessons learned from pathogens. Mol. Immunol. 114, 49–61. https://doi.org/ 10.1016/j.molimm.2019.07.018. Farias, L.P., Krautz-Peterson, G., Tararam, C.A., et al., 2013. On the three-finger protein domain fold and CD59-like proteins in Schistosoma mansoni. PLoS Negl. Trop. Dis. 7 (10), e2482. https://doi.org/10.1371/journal.pntd.0002482. Farkas, I., Baranyi, L., Ishikawa, Y., et al., 2002. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9. J. Physiol. 539 (2), 537–545. https://doi.org/10.1113/jphysiol.2001.013381. Favoreel, H.W., Nauwynck, H.J., Pensaert, M.B., 1999. Role of the cytoplasmic tail of gE in antibody-induced redistribution of viral glycoproteins expressed on pseudorabiesvirus-infected cells. Virology 259 (1), 141–147. https://doi.org/10.1006/ viro.1999.9749. Fernandez, H.N., Henson, P.M., Otani, A., Hugli, T.E., 1978. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J. Immunol. Baltim. Md (1950) 120 (1), 109–115. Ferreira, V., Valck, C., S´ anchez, G., et al., 2004a. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J. Immunol. 172 (5), 3042–3050. https://doi.org/10.4049/ jimmunol.172.5.3042. Ferreira, V., Molina, M.C., Valck, C., et al., 2004b. Role of calreticulin from parasites in its interaction with vertebrate hosts. Mol. Immunol. 40 (17), 1279–1291. https:// doi.org/10.1016/j.molimm.2003.11.018. Ferreira, V.P., Pangburn, M.K., Cort´ es, C., 2010. Complement control protein factor H: The good, the bad, and the inadequate. Mol. Immunol. 47 (13), 2187–2197. https:// doi.org/10.1016/j.molimm.2010.05.007. Figueira, M.A., Ram, S., Goldstein, R., Hood, D.W., Moxon, E.R., Pelton, S.I., 2007. Role of complement in defense of the middle ear revealed by restoring the virulence of nontypeable Haemophilus influenzae siaB mutants. Infect. Immun. 75 (1), 325–333. https://doi.org/10.1128/IAI.01054-06. Figueroa, J.E., Densen, P., 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4 (3), 359–395. https://doi.org/10.1128/ CMR.4.3.359. Fingeroth, J.D., Weis, J.J., Tedder, T.F., Strominger, J.L., Biro, P.A., Fearon, D.T., 1984. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. 81 (14), 4510–4514. https://doi.org/10.1073/pnas.81.14.4510. Fischer, E., Ouaissi, M.A., Velge, P., Cornette, J., Kazatchkine, M.D., 1988. gp 58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway. Immunology 65 (2), 299–303. Fishelson, Z., 1991. Complement evasion by parasites: search for “Achilles’ heel”. Clin. Exp. Immunol. 86 (Suppl. 1), 47–52. Flude, B.M., Nannetti, G., Mitchell, P., et al., 2021. Targeting the complement serine protease MASP-2 as a therapeutic strategy for coronavirus infections. Viruses 13 (2), 312. https://doi.org/10.3390/v13020312. Fraga, T.R., Isaac, L., Barbosa, A.S., 2016. Complement evasion by pathogenic Leptospira. Front. Immunol. 7. https://doi.org/10.3389/fimmu.2016.00623. Frank, I., Friedman, H.M., 1989. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. J. Virol. 63 (11), 4479–4488. https://doi.org/10.1128/JVI.63.11.4479-4488.1989. Frevert, U., Reinwald, E., 1990. Trypanosoma congolense bloodstream forms evade complement lysis in vitro by shedding of immune complexes. Eur. J. Cell Biol. 52 (2), 264–269. Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J. Immunol. Baltim. Md. 1950. 1986;137(5):1636-1641. Füst, G., Ujhelyi, E., Hidv´ egi, T., et al., 1991. The complement system in HIV disease. Immunol. Invest. 20 (2), 231–241. https://doi.org/10.3109/08820139109050792. Gale, C., Finkel, D., Tao, N., et al., 1996. Cloning and expression of a gene encoding an integrin-like protein in Candida albicans. Proc. Natl. Acad. Sci. USA 93 (1), 357–361. https://doi.org/10.1073/pnas.93.1.357. Garred, P., Mollnes, T.E., Lea, T., Fischer, E., 1988. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Scand. J. Immunol. 27 (3), 319–327. https://doi.org/10.1111/ j.1365-3083.1988.tb02353.x. Gilbert, M., Watson, D.C., Cunningham, A.M., Jennings, M.P., Young, N.M., Wakarchuk, W.W., 1996. Cloning of the lipooligosaccharide α -2,3-sialyltransferase from the bacterial pathogens Neisseria meningitidis and Neisseria gonorrhoeae. J. Biol. Chem. 271 (45), 28271–28276. https://doi.org/10.1074/jbc.271.45.28271. Girgis, N.M., Dehaven, B.C., Fan, X., Viner, K.M., Shamim, M., Isaacs, S.N., 2008. Cell surface expression of the vaccinia virus complement control protein is mediated by interaction with the viral A56 protein and protects infected cells from complement attack. J. Virol. 82 (9), 4205–4214. https://doi.org/10.1128/JVI.02426-07. Gonz´ alez, A., Valck, C., S´ anchez, G., et al., 2015. Trypanosoma cruzi calreticulin topographical variations in parasites infecting murine macrophages. Am. J. Trop. Med. Hyg. 92 (5), 887–897. https://doi.org/10.4269/ajtmh.14-0497. G¨ otz, M.P., Skjoedt, M.O., Bayarri-Olmos, R., et al., 2022. Lectin pathway enzyme MASP2 and downstream complement activation in COVID-19. J. Innate Immun. 15 (1), 1–14. https://doi.org/10.1159/000525508. Gulati, S., Sastry, K., Jensenius, J.C., Rice, P.A., Ram, S., 2002. Regulation of the mannan-binding lectin pathway of complement on Neisseria gonorrhoeae by C1inhibitor and α 2-macroglobulin. J. Immunol. 168 (8), 4078–4086. https://doi.org/ 10.4049/jimmunol.168.8.4078. de Haas, C.J.C., Veldkamp, K.E., Peschel, A., et al., 2004. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med. 199 (5), 687–695. https://doi.org/10.1084/jem.20031636. Hair, P.S., Gronemus, J.Q., Crawford, K.B., et al., 2010. Human astrovirus coat protein binds C1q and MBL and inhibits the classical and lectin pathways of complement activation. Mol. Immunol. 47 (4), 792–798. https://doi.org/10.1016/j. molimm.2009.10.006. Hallstr¨ om T, Siegel C, M¨ orgelin M, Kraiczy P, Skerka C, Zipfel PF. CspA from Borrelia burgdorferi inhibits the terminal complement pathway Cassone A, ed.. mBio 2013;4 (4):Cassone A, ed. doi:https://doi.org/10.1128/mBio.00481-13. Hammerschmidt, C., Klevenhaus, Y., Koenigs, A., et al., 2016. BGA66 and BGA71 facilitate complement resistance of Borrelia bavariensis by inhibiting assembly of the membrane attack complex. Mol. Microbiol. 99 (2), 407–424. https://doi.org/ 10.1111/mmi.13239. Hammerschmidt, S., Agarwal, V., Kunert, A., Haelbich, S., Skerka, C., Zipfel, P.F., 2007. The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J. Immunol. Baltim. Md. 1950 178 (9), 5848–5858. https://doi.org/10.4049/ jimmunol.178.9.5848. Hart, T., Nguyen, N.T.T., Nowak, N.A., et al., 2018. Polymorphic factor H-binding activity of CspA protects Lyme borreliae from the host complement in feeding ticks to facilitate tick-to-host transmission. Samuels DS, ed. PLOS Pathog. 14 (5), e1007106. https://doi.org/10.1371/journal.ppat.1007106. Hartmann, K., Corvey, C., Skerka, C., et al., 2006. Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1. Mol. Microbiol. 61 (5), 1220–1236. https://doi.org/10.1111/j.1365-2958.2006.05318.x. Heeger, P.S., Lalli, P.N., Lin, F., et al., 2005. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201 (10), 1523–1530. https://doi.org/ 10.1084/jem.20041967. Heesterbeek, D.A., Bardoel, B.W., Parsons, E.S., et al., 2019. Bacterial killing by complement requires membrane attack complex formation via surface-bound C5 convertases. EMBO J. 38 (4), e99852. https://doi.org/10.15252/embj.201899852. Henrique, P.M., Marques, T., da Silva, M.V., et al., 2016. Correlation between the virulence of T. cruzi strains, complement regulatory protein expression levels, and the ability to elicit lytic antibody production. Exp. Parasitol. 170, 66–72. https://doi. org/10.1016/j.exppara.2016.09.001. Hermoso, T., Fishelson, Z., Becker, S.I., Hirschberg, K., Jaffe, C.L., 1991. Leishmanial protein kinases phosphorylate components of the complement system. EMBO J. 10 (13), 4061–4067. https://doi.org/10.1002/j.1460-2075.1991.tb04982.x. Hess, C., Kemper, C., 2016. Complement-mediated regulation of metabolism and basic cellular processes. Immunity 45 (2), 240–254. https://doi.org/10.1016/j. immuni.2016.08.003. Hirsch, R.L., Griffin, D.E., Winkelstein, J.A., 1981. Host modification of Sindbis virus sialic acid content influences alternative complement pathway activation and virus clearance. J. Immunol. Baltim. Md. 1950 127 (5), 1740–1743. Hirsch, R.L., Griffin, D.E., Winkelstein, J.A., 1983. Natural immunity to Sindbis virus is influenced by host tissue sialic acid content. Proc. Natl. Acad. Sci. USA 80 (2), 548–550. https://doi.org/10.1073/pnas.80.2.548. Hostetter, M.K., 2008. The iC3b receptor of Candida albicans and its roles in pathogenesis. Vaccine 26 (Suppl. 8), I108–I112. https://doi.org/10.1016/j. vaccine.2008.11.056. Hourcade, D.E., Mitchell, L., Kuttner-Kondo, L.A., Atkinson, J.P., Medof, M.E., 2002. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. J. Biol. Chem. 277 (2), 1107–1112. https://doi.org/10.1074/jbc. M109322200. Hsieh, C.L., Werner, A.P., Leist, S.R., et al., 2021. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Rep. 37 (5), 109929. https://doi.org/10.1016/j. celrep.2021.109929. Hudson, P.N., Self, J., Weiss, S., et al., 2012. Elucidating the role of the complement control protein in monkeypox pathogenicity. PLoS One 7 (4), e35086. https://doi. org/10.1371/journal.pone.0035086. Hung, S.L., Peng, C., Kostavasili, I., et al., 1994. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology 203 (2), 299–312. https://doi.org/10.1006/viro.1994.1488. Hurler, L., Toonen, E.J.M., Kajd´ acsi, E., et al., 2022. Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP1/C1-INH complexes using novel ELISAs. Front. Immunol. 13, 1039765. https://doi. org/10.3389/fimmu.2022.1039765. Ib´ a˜ nez-Escribano, A., Nogal-Ruiz, J.J., P´ erez-Serrano, J., G´ omez-Barrio, A., Escario, J.A., Alderete, J.F., 2015. Sequestration of host-CD59 as potential immune evasion strategy of Trichomonas vaginalis. Acta Trop. 149, 1–7. https://doi.org/10.1016/j. actatropica.2015.05.003. A.A. Nowacka et al. Immunobiology 230 (2025) 153126 16 Inal, J., Miot, S., Schifferli, J.A., 2005. The complement inhibitor, CRIT, undergoes clathrin-dependent endocytosis. Exp. Cell Res. 310 (1), 54–65. https://doi.org/ 10.1016/j.yexcr.2005.07.003. Inal, J.M., Schifferli, J.A., 2002. Complement C2 receptor inhibitor trispanning and the beta-chain of C4 share a binding site for complement C2. J. Immunol. Baltim. Md. 1950 168 (10), 5213–5221. https://doi.org/10.4049/jimmunol.168.10.5213. Isaacs, S.N., Kotwal, G.J., Moss, B., 1992. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. USA 89 (2), 628–632. https://doi. org/10.1073/pnas.89.2.628. Jha, P., Kotwal, G.J., 2003. Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J. Biosci. 28 (3), 265–271. https://doi.org/ 10.1007/BF02970146. Johnson, D.C., Feenstra, V., 1987. Identification of a novel herpes simplex virus type 1induced glycoprotein which complexes with gE and binds immunoglobulin. J. Virol. 61 (7), 2208–2216. https://doi.org/10.1128/JVI.61.7.2208-2216.1987. Johnson, D.C., Frame, M.C., Ligas, M.W., Cross, A.M., Stow, N.D., 1988. Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI. J. Virol. 62 (4), 1347–1354. https://doi.org/10.1128/ JVI.62.4.1347-1354.1988. Johnson, J.B., Borisevich, V., Rockx, B., Parks, G.D., 2015. A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3b. J. Virol. 89 (2), 989–998. https://doi.org/10.1128/JVI.02427-14. Joiner, K.A., Hammer, C.H., Brown, E.J., Frank, M.M., 1982. Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane. J. Exp. Med. 155 (3), 809–819. https://doi. org/10.1084/jem.155.3.809. Joiner, K.A., daSilva, W.D., Rimoldi, M.T., Hammer, C.H., Sher, A., Kipnis, T.L., 1988. Biochemical characterization of a factor produced by trypomastigotes of Trypanosoma cruzi that accelerates the decay of complement C3 convertases. J. Biol. Chem. 263 (23), 11327–11335. Kahn, S.J., Wleklinski, M., Ezekowitz, R.A., Coder, D., Aruffo, A., Farr, A., 1996. The major surface glycoprotein of Trypanosoma cruzi amastigotes are ligands of the human serum mannose-binding protein. Infect. Immun. 64 (7), 2649–2656. https:// doi.org/10.1128/iai.64.7.2649-2656.1996. Kennedy, A.T., Wijeyewickrema, L.C., Huglo, A., et al., 2017. Recruitment of human C1 esterase inhibitor controls complement activation on blood stage Plasmodium falciparum merozoites. J. Immunol. Baltim. Md. 1950 198 (12), 4728–4737. https:// doi.org/10.4049/jimmunol.1700067. Kenno, S., Speth, C., Rambach, G., et al., 2018. Candida albicans factor H binding molecule Hgt1p – a low glucose-induced transmembrane protein is trafficked to the cell wall and impairs phagocytosis and killing by human neutrophils. Front. Microbiol. 9, 3319. https://doi.org/10.3389/fmicb.2018.03319. Khattab, A., Rezola, M., Barroso, M., et al., 2022. Hijacking the human complement inhibitor C4b-binding protein by the sporozoite stage of the Plasmodium falciparum parasite. Front. Immunol. 13, 1051161. https://doi.org/10.3389/ fimmu.2022.1051161. Khera, R., Das, N., 2009. Complement receptor 1: disease associations and therapeutic implications. Mol. Immunol. 46 (5), 761–772. https://doi.org/10.1016/j. molimm.2008.09.026. Kim, H., Meyer, K., Di Bisceglie, A.M., Ray, R., 2013. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J. Virol. 87 (10), 5858–5867. https://doi.org/10.1128/JVI.00174-13. Kim, H., Meyer, K., Di Bisceglie, A.M., Ray, R., 2014. Inhibition of c3 convertase activity by hepatitis C virus as an additional lesion in the regulation of complement components. PLoS One 9 (7), e101422. https://doi.org/10.1371/journal. pone.0101422. Kim, J.H., Excler, J.L., Michael, N.L., 2015. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu. Rev. Med. 66, 423–437. https://doi.org/10.1146/annurev-med-052912-123749. Kim, Y.U., Hong, Y., 2007. Functional analysis of the first mannosyltransferase (PIG-M) involved in glycosylphosphatidylinositol synthesis in Plasmodium falciparum. Mol. Cell 24 (2), 294–300. Kipnis, T.L., Joiner, K.A., da Silva, W.D., Rimoldi, M.T., Hammer, C.H., Sher, A., 1988. Identification of membrane components of Trypanosoma cruzi modulators of complement system. Mem. Inst. Oswaldo Cruz 83 (Suppl. 1), 571–575. https://doi. org/10.1590/s0074-02761988000500069. Kiyuka, P.K., Meri, S., Khattab, A., 2020. Complement in malaria: immune evasion strategies and role in protective immunity. FEBS Lett. 594 (16), 2502–2517. https:// doi.org/10.1002/1873-3468.13772. Klos, A., Tenner, A.J., Johswich, K.O., Ager, R.R., Reis, E.S., K¨ ohl, J., 2009. The role of the anaphylatoxins in health and disease. Mol. Immunol. 46 (14), 2753–2766. https://doi.org/10.1016/j.molimm.2009.04.027. Koch, T.K., Reuter, M., Barthel, D., et al., 2012. Staphylococcus aureus proteins Sbi and Efb recruit human plasmin to degrade complement C3 and C3b. Bereswill S, ed. PLoS ONE 7 (10), e47638. https://doi.org/10.1371/journal.pone.0047638. Kolev, M., Le Friec, G., Kemper, C., 2013. The role of complement in CD4+T cell homeostasis and effector functions. Semin. Immunol. 25 (1), 12–19. https://doi.org/ 10.1016/j.smim.2013.04.012. Kolev, M., Dimeloe, S., Le Friec, G., et al., 2015. Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses. Immunity 42 (6), 1033–1047. https://doi.org/10.1016/j.immuni.2015.05.024. Kostavasili, I., Sahu, A., Friedman, H.M., Eisenberg, R.J., Cohen, G.H., Lambris, J.D., 1997. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J. Immunol. Baltim. Md. 1950 158 (4), 1763–1771. Kotwal, G.J., Moss, B., 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335 (6186), 176–178. https://doi. org/10.1038/335176a0. Kotwal, G.J., Isaacs, S.N., McKenzie, R., Frank, M.M., Moss, B., 1990. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250 (4982), 827–830. https://doi.org/10.1126/science.2237434. Kov´ acs, K.G., M´ acsik-Valent, B., Matk´ o, J., Bajtay, Z., Erdei, A., 2021. Revisiting the coreceptor function of complement receptor type 2 (CR2, CD21); coengagement with the B-cell receptor inhibits the activation, proliferation, and antibody production of human B cells. Front. Immunol. 12, 620427. https://doi.org/10.3389/ fimmu.2021.620427. Kulik, L., Chen, K., Huber, B.T., Holers, V.M., 2011. Human complement receptor type 2 (CR2/CD21) transgenic mice provide an in vivo model to study immunoregulatory effects of receptor antagonists. Mol. Immunol. 48 (6–7), 883–894. https://doi.org/ 10.1016/j.molimm.2010.12.019. Kulkarni, H.S., Elvington, M.L., Perng, Y.C., et al., 2019. Intracellular C3 protects human airway epithelial cells from stress-associated cell death. Am. J. Respir. Cell Mol. Biol. 60 (2), 144–157. https://doi.org/10.1165/rcmb.2017-0405OC. Kunert, A., Losse, J., Gruszin, C., et al., 2007. Immune evasion of the human pathogen Pseudomonas aeruginosa: elongation factor Tuf is a factor H and plasminogen binding protein. J. Immunol. 179 (5), 2979–2988. https://doi.org/10.4049/ jimmunol.179.5.2979. Kuo, C.F., Lin, Y.S., Chuang, W.J., Wu, J.J., Tsao, N., 2008. Degradation of complement 3 by streptococcal pyrogenic exotoxin B inhibits complement activation and neutrophil opsonophagocytosis. Infect. Immun. 76 (3), 1163–1169. https://doi.org/ 10.1128/IAI.01116-07. Lalli, P.N., Strainic, M.G., Yang, M., Lin, F., Medof, M.E., Heeger, P.S., 2008. Locally produced C5a binds to T cell–expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood 112 (5), 1759–1766. https://doi.org/ 10.1182/blood-2008-04-151068. Lambris, J.D., Ricklin, D., Geisbrecht, B.V., 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6 (2), 132–142. https://doi.org/10.1038/ nrmicro1824. Lapeyraque, A.L., Malina, M., Fremeaux-Bacchi, V., et al., 2011. Eculizumab in severe Shiga-Toxin–associated HUS. N. Engl. J. Med. 364 (26), 2561–2563. https://doi.org/ 10.1056/NEJMc1100859. Larsen, M.D., Quintana, M.D.P., Ditlev, S.B., et al., 2019. Evasion of classical complement pathway activation on Plasmodium falciparum-infected erythrocytes opsonized by PfEMP1-specific IgG. Front. Immunol. 9, 3088. https://doi.org/10.3389/ fimmu.2018.03088. Likos, A.M., Sammons, S.A., Olson, V.A., et al., 2005. A tale of two clades: monkeypox viruses. J. Gen. Virol. 86 (Pt 10), 2661–2672. https://doi.org/10.1099/vir.0.812150. Liszewski, M.K., Post, T.W., Atkinson, J.P., 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9 (1), 431–455. https://doi.org/10.1146/annurev. iy.09.040191.002243. Liszewski, M.K., Leung, M.K., Hauhart, R., et al., 2006. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation. J. Immunol. Baltim. Md. 1950 176 (6), 3725–3734. https://doi.org/10.4049/jimmunol.176.6.3725. Liu, J., Miwa, T., Hilliard, B., et al., 2005. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J. Exp. Med. 201 (4), 567–577. https:// doi.org/10.1084/jem.20040863. Locke, J.W., 2019. Complement evasion in borrelia spirochetes: mechanisms and opportunities for intervention. Antibiot. Basel Switz. 8 (2), 80. https://doi.org/ 10.3390/antibiotics8020080. Lubbers, R., Sutherland, J.S., Goletti, D., et al., 2018. Complement component C1q as serum biomarker to detect active tuberculosis. Front. Immunol. 9, 2427. https://doi. org/10.3389/fimmu.2018.02427. Lubinski, J.M., Lazear, H.M., Awasthi, S., Wang, F., Friedman, H.M., 2011. The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J. Virol. 85 (7), 3239–3249. https://doi.org/10.1128/JVI.02509-10. Luo, S., Poltermann, S., Kunert, A., Rupp, S., Zipfel, P.F., 2009. Immune evasion of the human pathogenic yeast Candida albicans: Pra1 is a Factor H, FHL-1 and plasminogen binding surface protein. Mol. Immunol. 47 (2–3), 541–550. https://doi. org/10.1016/j.molimm.2009.07.017. Luo, S., Blom, A.M., Rupp, S., et al., 2011. The pH-regulated antigen 1 of Candida albicans binds the human complement inhibitor C4b-binding protein and mediates fungal complement evasion. J. Biol. Chem. 286 (10), 8021–8029. https://doi.org/10.1074/ jbc.M110.130138. Luo, S., Dasari, P., Reiher, N., et al., 2018. The secreted Candida albicans protein Pra1 disrupts host defense by broadly targeting and blocking complement C3 and C3 activation fragments. Mol. Immunol. 93, 266–277. https://doi.org/10.1016/j. molimm.2017.07.010. Lynskey, N.N., Reglinski, M., Calay, D., et al., 2017. Multi-functional mechanisms of immune evasion by the streptococcal complement inhibitor C5a peptidase. Bessen DE, ed. PLOS Pathog. 13 (8), e1006493. https://doi.org/10.1371/journal. ppat.1006493. Magda, M., Boschloo, W., Bettoni, S., et al., 2025. Acinetobacter baumannii clinical isolates resist complement-mediated lysis by inhibiting the complement cascade and improperly depositing MAC. J. Innate Immun. 17 (1), 112–125. https://doi.org/ 10.1159/000543664. A.A. Nowacka et al. Immunobiology 230 (2025) 153126 17 Mahajan, S., Jacob, A., Kelkar, A., et al., 2021. Local complement factor H protects kidney endothelial cell structure and function. Kidney Int. 100 (4), 824–836. https:// doi.org/10.1016/j.kint.2021.05.033. Malekshahi, Z., Schiela, B., Bernklau, S., Banki, Z., Würzner, R., Stoiber, H., 2020. Interference of the zika virus E-protein with the membrane attack complex of the complement system. Front. Immunol. 11, 569549. https://doi.org/10.3389/ fimmu.2020.569549. Marcinkiewicz, A.L., Kraiczy, P., Lin, Y.P., 2017. There Is a method to the madness: strategies to study host complement evasion by lyme disease and relapsing fever spirochetes. Front. Microbiol. 8. https://doi.org/10.3389/fmicb.2017.00328. Mayer, M.M., 1972. Mechanism of cytolysis by complement. Proc. Natl. Acad. Sci. USA 69 (10), 2954–2958. https://doi.org/10.1073/pnas.69.10.2954. Mazumdar, B., Kim, H., Meyer, K., et al., 2012. Hepatitis C virus proteins inhibit C3 complement production. J. Virol. 86 (4), 2221–2228. https://doi.org/10.1128/ JVI.06577-11. McKenzie, R., Kotwal, G.J., Moss, B., Hammer, C.H., Frank, M.M., 1992. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166 (6), 1245–1250. https://doi.org/10.1093/infdis/166.6.1245. Mejia, P., Diez-Silva, M., Kamena, F., et al., 2016. Human C1-inhibitor suppresses malaria parasite invasion and cytoadhesion via binding to parasite glycosylphosphatidylinositol and host cell receptors. J. Infect. Dis. 213 (1), 80–89. https://doi.org/10.1093/infdis/jiv439. Melchers, F., Erdei, A., Schulz, T., Dierich, M.P., 1985. Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature 317 (6034), 264–267. https://doi.org/10.1038/317264a0. Mellors, J., Tipton, T., Longet, S., Carroll, M., 2020. Viral evasion of the complement system and its importance for vaccines and therapeutics. Front. Immunol. 11, 1450. https://doi.org/10.3389/fimmu.2020.01450. Meri, T., Hartmann, A., Lenk, D., et al., 2002. The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect. Immun. 70 (9), 5185–5192. https://doi.org/10.1128/IAI.70.9.5185-5192.2002. Merino, S., Camprubí, S., Albertí, S., Benedí, V.J., Tom´ as, J.M., 1992. Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing. Infect. Immun. 60 (6), 2529–2535. https://doi.org/10.1128/iai.60.6.2529-2535.1992. Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., Roumenina, L.T., 2015a. Complement system part I – molecular mechanisms of activation and regulation. Front. Immunol. 6 (JUN), 1–30. https://doi.org/10.3389/fimmu.2015.00262. Merle, N.S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V., Roumenina, L.T., 2015b. Complement system Part II: role in immunity. Front. Immunol. 6, 257. https://doi.org/10.3389/fimmu.2015.00257. Messerer, D.A.C., Denk, S., F¨ ohr, K.J., et al., 2018. Complement C5a alters the membrane potential of neutrophils during hemorrhagic shock. Mediat. Inflamm. 2018, 2052356. https://doi.org/10.1155/2018/2052356. Miller, C.G., Shchelkunov, S.N., Kotwal, G.J., 1997. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology 229 (1), 126–133. https://doi.org/10.1006/viro.1996.8396. Miller, H.W., Tam, T.S.Y., Ralston, K.S., 2022. Entamoeba histolytica develops resistance to complement deposition and lysis after acquisition of human complementregulatory proteins through trogocytosis. mBio 13 (2), e0316321. https://doi.org/ 10.1128/mbio.03163-21. Mitchell, T.J., Andrew, P.W., 1997. Biological properties of pneumolysin. Microb. Drug Resist. Larchmt. N. 3 (1), 19–26. https://doi.org/10.1089/mdr.1997.3.19. Mollnes, T.E., Lea, T., Harboe, M., Tschopp, J., 1985. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand. J. Immunol. 22 (2), 183–195. https://doi.org/10.1111/j.13653083.1985.tb01870.x. Monem, S., Furmanek-Blaszk, B., Łupkowska, A., Kuczy´ nska-Wi´ snik, D., StojowskaSwędrzy´ nska, K., Laskowska, E., 2020. Mechanisms protecting Acinetobacter baumannii against multiple stresses triggered by the host immune response, antibiotics and outside-host environment. Int. J. Mol. Sci. 21 (15), 5498. https://doi. org/10.3390/ijms21155498. Montefiori, D.C., Cornell, R.J., Zhou, J.Y., Zhou, J.T., Hirsch, V.M., Johnson, P.R., 1994. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205 (1), 82–92. https://doi.org/10.1006/ viro.1994.1622. Moore, S.R., Menon, S.S., Cortes, C., Ferreira, V.P., 2021. Hijacking factor H for complement immune evasion. Front. Immunol. 12, 602277. https://doi.org/ 10.3389/fimmu.2021.602277. Morgan, B.P., 1999. Regulation of the complement membrane attack pathway. Crit. Rev. Immunol. 19 (3), 173–198. Morris, A.C., Brittan, M., Wilkinson, T.S., et al., 2011. C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients. Blood 117 (19), 5178–5188. https://doi.org/10.1182/blood-2010-08-304667. Mosser, D.M., Springer, T.A., Diamond, M.S., 1992. Leishmania promastigotes require opsonic complement to bind to the human leukocyte integrin Mac-1 (CD11b/CD18). J. Cell Biol. 116 (2), 511–520. https://doi.org/10.1083/jcb.116.2.511. Moulton, E.A., Bertram, P., Chen, N., Buller, R.M.L., Atkinson, J.P., 2010. Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement. J. Virol. 84 (18), 9128–9139. https://doi. org/10.1128/JVI.02677-09. Nag, J., Mukesh, R.K., Suma, S.M., Kunnakkadan, U., Kumar, N.A., Johnson, J.B., 2020. A factor I-like activity associated with chikungunya virus contributes to its resistance to the human complement system. J. Virol. 94 (7). https://doi.org/10.1128/ JVI.02062-19 e02062-19. Norris, K.A., 1996a. Microbial evasion of complement-mediated clearance. J. Liposome Res. 6 (1), 117–132. https://doi.org/10.3109/08982109609037205. Norris, K.A., 1996b. Ligand-binding renders the 160 kDa Trypanosoma cruzi complement regulatory protein susceptible to proteolytic cleavage. Microb. Pathog. 21 (4), 235–248. https://doi.org/10.1006/mpat.1996.0058. Norris, K.A., 1998. Stable transfection of Trypanosoma cruzi epimastigotes with the trypomastigote-specific complement regulatory protein cDNA confers complement resistance. Infect. Immun. 66 (6), 2460–2465. https://doi.org/10.1128/ IAI.66.6.2460-2465.1998. Norris, K.A., Schrimpf, J.E., 1994. Biochemical analysis of the membrane and soluble forms of the complement regulatory protein of Trypanosoma cruzi. Infect. Immun. 62 (1), 236–243. https://doi.org/10.1128/iai.62.1.236-243.1994. Norris, K.A., Bradt, B., Cooper, N.R., So, M., 1991. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J. Immunol. Baltim. Md. 1950 147 (7), 2240–2247. Norris, K.A., Harth, G., So, M., 1989. Purification of a Trypanosoma cruzi membrane glycoprotein which elicits lytic antibodies. Infect. Immun. 57 (8), 2372–2377. https://doi.org/10.1128/iai.57.8.2372-2377.1989. Norris, K.A., Schrimpf, J.E., Szabo, M.J., 1997. Identification of the gene family encoding the 160-kilodalton Trypanosoma cruzi complement regulatory protein. Infect. Immun. 65 (2), 349–357. https://doi.org/10.1128/iai.65.2.349-357.1997. Ogembo, J.G., Kannan, L., Ghiran, I., et al., 2013. Human complement receptor type 1/ CD35 is an Epstein-Barr virus receptor. Cell Rep. 3 (2), 371–385. https://doi.org/ 10.1016/j.celrep.2013.01.023. Oladiran, A., Belosevic, M., 2010. Trypanosoma carassii calreticulin binds host complement component C1q and inhibits classical complement pathway-mediated lysis. Dev. Comp. Immunol. 34 (4), 396–405. https://doi.org/10.1016/j. dci.2009.11.005. Onyilagha, C., Uzonna, J.E., 2019. Host immune responses and immune evasion strategies in African trypanosomiasis. Front. Immunol. 10, 2738. https://doi.org/ 10.3389/fimmu.2019.02738. Oppermann, M., Würzner, R., 2010. Modern determination of complement activation. Semin. Thromb. Hemost. 36 (6), 611–619. https://doi.org/10.1055/s-00301262882. Orth, D., Würzner, R., 2010. Complement in typical hemolytic uremic syndrome. Semin. Thromb. Hemost. 36 (6), 620–624. https://doi.org/10.1055/s-0030-1262883. Orth, D., Khan, A.B., Naim, A., et al., 2009. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J. Immunol. 182 (10), 6394–6400. https://doi.org/10.4049/jimmunol.0900151. Orth-H¨ oller, D., Riedl, M., Würzner, R., 2011. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS – perfect example for a fast track from bench to bedside. EMBO Mol. Med. 3 (11), 617–619. https://doi.org/10.1002/ emmm.201100169. Ouaissi, A., Cornette, J., Taibi, A., Velge, P., Capron, A., 1988. Major surface immunogens of Trypanosoma cruzi trypomastigotes. Mem. Inst. Oswaldo Cruz 83 (Suppl. 1), 502. https://doi.org/10.1590/s0074-02761988000500058. Ouaissi, M.A., Afchain, D., Capron, A., Grimaud, J.A., 1984. Fibronectin receptors on Trypanosoma cruzi trypomastigotes and their biological function. Nature 308 (5957), 380–382. https://doi.org/10.1038/308380a0. Ouaissi, M.A., Cornette, J., Capron, A., 1986. Identification and isolation of Trypanosoma cruzi trypomastigote cell surface protein with properties expected of a fibronectin receptor. Mol. Biochem. Parasitol. 19 (3), 201–211. https://doi.org/10.1016/01666851(86)90002-2. Parizade, M., Arnon, R., Lachmann, P.J., Fishelson, Z., 1994. Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59. J. Exp. Med. 179 (5), 1625–1636. https://doi.org/10.1084/jem.179.5.1625. Pausa, M., Pellis, V., Cinco, M., et al., 2003. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule. J. Immunol. Baltim. Md. 1950 170 (6), 3214–3222. https://doi.org/10.4049/jimmunol.170.6.3214. Pavlov, V., Raedler, H., Yuan, S., et al., 2008. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. J. Immunol. 181 (7), 4580–4589. https://doi.org/10.4049/jimmunol.181.7.4580. Peffault de Latour, R., Bergeron, A., Lengline, E., et al., 2020. Complement C5 inhibition in patients with COVID-19 – a promising target? Haematologica 105 (12), 2847–2850. https://doi.org/10.3324/haematol.2020.260117. Pereira-Filho, A.A., Queiroz, D.C., Saab, N.A.A., et al., 2023. Evasion of the complement system by Leishmania through the uptake of C4bBP, a complement regulatory protein, and probably by the action of GP63 on C4b molecules deposited on parasite surface. Acta Trop. 242, 106908. https://doi.org/10.1016/j. actatropica.2023.106908. Postma, B., Poppelier, M.J., Van Galen, J.C., et al., 2004. Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J. Immunol. 172 (11), 6994–7001. https://doi.org/10.4049/ jimmunol.172.11.6994. Potempa, M., Potempa, J., 2012. Protease-dependent mechanisms of complement evasion by bacterial pathogens. bchm 393 (9), 873–888. https://doi.org/10.1515/ hsz-2012-0174. Preissner, K.P., Podack, E.R., Müller-Eberhard, H.J., 1989. SC5b-7, SC5b-8 and SC5b-9 complexes of complement: ultrastructure and localization of the S-protein (vitronectin) within the macromolecules. Eur. J. Immunol. 19 (1), 69–75. https:// doi.org/10.1002/eji.1830190112. Principato, S., Pizza, M., Rappuoli, R., 2020. Meningococcal factor H binding protein as immune evasion factor and vaccine antigen. FEBS Lett. 594 (16), 2657–2669. https://doi.org/10.1002/1873-3468.13793. A.A. Nowacka et al. Immunobiology 230 (2025) 153126 18 Puentes, S.M., Da Silva, R.P., Sacks, D.L., Hammer, C.H., Joiner, K.A., 1990. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9. J. Immunol. Baltim. Md. 1950 145 (12), 4311–4316. Qerqez, A.N., Silva, R.P., Maynard, J.A., 2023. Outsmarting pathogens with antibody engineering. Annu. Rev. Chem. Biomol. Eng. 14, 217–241. https://doi.org/10.1146/ annurev-chembioeng-101121-084508. Ram, S., Sharma, A.K., Simpson, S.D., et al., 1998. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J. Exp. Med. 187 (5), 743–752. https://doi.org/10.1084/jem.187.5.743. Rambach, G., Dum, D., Mohsenipour, I., et al., 2010. Secretion of a fungal protease represents a complement evasion mechanism in cerebral aspergillosis. Mol. Immunol. 47 (7–8), 1438–1449. https://doi.org/10.1016/j.molimm.2010.02.010. Ramírez, G., Valck, C., Molina, M.C., et al., 2011. Trypanosoma cruzi calreticulin: a novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity. Immunobiology 216 (1–2), 265–273. https://doi.org/10.1016/j. imbio.2010.04.001. Ramírez, G., Valck, C., Aguilar, L., et al., 2012. Roles of Trypanosoma cruzi calreticulin in parasite-host interactions and in tumor growth. Mol. Immunol. 52 (3–4), 133–140. https://doi.org/10.1016/j.molimm.2012.05.006. Ramírez-Toloza, G., Sosoniuk-Roche, E., Valck, C., Aguilar-Guzm´ an, L., Ferreira, V.P., Ferreira, A., 2020. Trypanosoma cruzi calreticulin: immune evasion, infectivity, and tumorigenesis. Trends Parasitol. 36 (4), 368–381. https://doi.org/10.1016/j. pt.2020.01.007. Ramm, L.E., Whitlow, M.B., Mayer, M.M., 1982. Transmembrane channel formation by complement: functional analysis of the number of C5b6, C7, C8, and C9 molecules required for a single channel. Proc. Natl. Acad. Sci. USA 79 (15), 4751–4755. https://doi.org/10.1073/pnas.79.15.4751. Ramos, R., Juri, M., Ramos, A., et al., 1991. An immunogenetically defined and immunodominant Trypanosoma cruzi antigen. Am. J. Trop. Med. Hyg. 44 (3), 314–322. https://doi.org/10.4269/ajtmh.1991.44.314. Rashidi, S., Mansouri, R., Ali-Hassanzadeh, M., Muro, A., Nguewa, P., ManzanoRom´ an, R., 2022. The defensive interactions of prominent infectious protozoan parasites: the host’s complement system. Biomolecules 12 (11), 1564. https://doi. org/10.3390/biom12111564. Rasti, N., Namusoke, F., Chˆ ene, A., et al., 2006. Nonimmune immunoglobulin binding and multiple adhesion characterize Plasmodium falciparum-infected erythrocytes of placental origin. Proc. Natl. Acad. Sci. USA 103 (37), 13795–13800. https://doi.org/ 10.1073/pnas.0601519103. Rathore, U., Saha, P., Kesavardhana, S., et al., 2017. Glycosylation of the core of the HIV1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. J. Biol. Chem. 292 (24), 10197–10219. https://doi.org/10.1074/jbc. M117.788919. Rautemaa, R., Jarvis, G.A., Marnila, P., Meri, S., 1998. Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59). Infect. Immun. 66 (5), 1928–1933. https://doi.org/10.1128/IAI.66.5.19281933.1998. Rautemaa, R., Rautelin, H., Puolakkainen, P., Kokkola, A., K¨ arkk¨ ainen, P., Meri, S., 2001. Survival of Helicobacter pylori from complement lysis by binding of GPI-anchored protectin (CD59). Gastroenterology 120 (2), 470–479. https://doi.org/10.1053/ gast.2001.21197. Reed, S.L., Ember, J.A., Herdman, D.S., DiScipio, R.G., Hugli, T.E., Gigli, I., 1995. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a. J. Immunol. Baltim. Md. 1950 155 (1), 266–274. Reiss, T., Theis, H.I., Gonzalez-Delgado, A., et al., 2021. Acquisition of human plasminogen facilitates complement evasion by the malaria parasite Plasmodium falciparum. Eur. J. Immunol. 51 (2), 490–493. https://doi.org/10.1002/ eji.202048718. Ribeiro, C.H., Lynch, N.J., Ferreira, A., et al., 2015. Deficiency in mannose-binding lectin-associated serine protease-2 does not increase susceptibility to Trypanosoma cruzi infection. Am. J. Trop. Med. Hyg. 92 (2), 320–324. https://doi.org/10.4269/ ajtmh.14-0236. Ries, J.I., Heß, M., Nouri, N., et al., 2022. CipA mediates complement resistance of Acinetobacter baumannii by formation of a factor I-dependent quadripartite assemblage. Front. Immunol. 13, 942482. https://doi.org/10.3389/ fimmu.2022.942482. Rimoldi, M.T., Sher, A., Heiny, S., Lituchy, A., Hammer, C.H., Joiner, K., 1988. Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases. Proc. Natl. Acad. Sci. USA 85 (1), 193–197. https://doi.org/10.1073/pnas.85.1.193. Rimoldi, M.T., Tenner, A.J., Bobak, D.A., Joiner, K.A., 1989. Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes. J. Clin. Invest. 84 (6), 1982–1989. https://doi. org/10.1172/JCI114388. Roberts, I.S., 1996. The biochemistry and genetics of capsular polysaccharide production in bacteria. Ann. Rev. Microbiol. 50 (1), 285–315. https://doi.org/10.1146/ annurev.micro.50.1.285. Rooijakkers, S.H.M., Van Strijp, J.A.G., 2007. Bacterial complement evasion. Mol. Immunol. 44 (1–3), 23–32. https://doi.org/10.1016/j.molimm.2006.06.011. Rosengard, A.M., Liu, Y., Nie, Z., Jimenez, R., 2002. Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc. Natl. Acad. Sci. USA 99 (13), 8808–8813. https://doi.org/10.1073/pnas.112220499. Rosenthal, L.A., Sutterwala, F.S., Kehrli, M.E., Mosser, D.M., 1996. Leishmania majorhuman macrophage interactions: cooperation between Mac-1 (CD11b/CD18) and complement receptor type 1 (CD35) in promastigote adhesion. Infect. Immun. 64 (6), 2206–2215. https://doi.org/10.1128/iai.64.6.2206-2215.1996. Roversi, P., Johnson, S., Caesar, J.J.E., et al., 2011. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc. Natl. Acad. Sci. 108 (31), 12839–12844. https://doi.org/10.1073/pnas.1102167108. Rudenko, G., 2011. African trypanosomes: the genome and adaptations for immune evasion. Essays Biochem. 51, 47–62. https://doi.org/10.1042/bse0510047. Ruggenenti, P., Di Marco, F., Cortinovis, M., et al., 2021. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One 16 (12), e0261113. https://doi.org/10.1371/journal.pone.0261113. Russell, D.G., 1987. The macrophage-attachment glycoprotein gp63 is the predominant C3-acceptor site on Leishmania mexicana promastigotes. Eur. J. Biochem. 164 (1), 213–221. https://doi.org/10.1111/j.1432-1033.1987.tb11013.x. Sahly, H., Keisari, Y., Ofek, I., 2009. Manno(rhamno)biose-containing capsular polysaccharides of Klebsiella pneumoniae enhance opsono-stimulation of human polymorphonuclear leukocytes. J. Innate Immun. 1 (2), 136–144. https://doi.org/ 10.1159/000154812. Sahoo, S., Murugavel, S., Devi, I.K., et al., 2013. Glyceraldehyde-3-phosphate dehydrogenase of the parasitic nematode Haemonchus contortus binds to complement C3 and inhibits its activity. Parasite Immunol. 35 (12), 457–467. https://doi.org/ 10.1111/pim.12058. Sahu, A., Isaacs, S.N., Soulika, A.M., Lambris, J.D., 1998. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J. Immunol. Baltim. Md. 1950 160 (11), 5596–5604. Saifuddin, M., Parker, C.J., Peeples, M.E., et al., 1995. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182 (2), 501–509. https://doi.org/10.1084/jem.182.2.501. Schmidt, C.Q., Kennedy, A.T., Tham, W.H., 2015. More than just immune evasion: hijacking complement by Plasmodium falciparum. Mol. Immunol. 67 (1), 71–84. https://doi.org/10.1016/j.molimm.2015.03.006. Sfyroera, G., Katragadda, M., Morikis, D., Isaacs, S.N., Lambris, J.D., 2005. Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J. Immunol. Baltim. Md. 1950 174 (4), 2143–2151. https://doi.org/10.4049/ jimmunol.174.4.2143. Shi, Y., Toet, H., Rathinasamy, V., et al., 2014. First insight into CD59-like molecules of adult Fasciola hepatica. Exp. Parasitol. 144, 57–64. https://doi.org/10.1016/j. exppara.2014.06.012. Siegel, C., Schreiber, J., Haupt, K., et al., 2008. Deciphering the ligand-binding sites in the Borrelia burgdorferi complement regulator-acquiring surface protein 2 required for interactions with the human immune regulators factor H and factor H-like protein 1. J. Biol. Chem. 283 (50), 34855–34863. https://doi.org/10.1074/jbc. M805844200. Sikorski, P.M., Commodaro, A.G., Grigg, M.E., 2020. Toxoplasma gondii recruits factor H and C4b-binding protein to mediate resistance to serum killing and promote parasite persistence in vivo. Front. Immunol. 10, 3105. https://doi.org/10.3389/ fimmu.2019.03105. Sikorski, P.M., Commodaro, A.G., Grigg, M.E., 2021. A protective and pathogenic role for complement during acute Toxoplasma gondii infection. Front. Cell. Infect. Microbiol. 11, 634610. https://doi.org/10.3389/fcimb.2021.634610. Simon, N., Lasonder, E., Scheuermayer, M., et al., 2013. Malaria parasites co-opt human factor H to prevent complement-mediated lysis in the mosquito midgut. Cell Host Microbe 13 (1), 29–41. https://doi.org/10.1016/j.chom.2012.11.013. Skattum, L., van Deuren, M., van der Poll, T., Truedsson, L., 2011. Complement deficiency states and associated infections. Mol. Immunol. 48 (14), 1643–1655. https://doi.org/10.1016/j.molimm.2011.05.001. Smith, S.A., Mullin, N.P., Parkinson, J., et al., 2000. Conserved surface-exposed K/R-X-K/ R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense. J. Virol. 74 (12), 5659–5666. https://doi.org/10.1128/jvi.74.12.5659-5666.2000. Song, W.C., 2012. Crosstalk between complement and toll-like receptors. Toxicol. Pathol. 40 (2), 174–182. https://doi.org/10.1177/0192623311428478. Sorbara, M.T., Foerster, E.G., Tsalikis, J., et al., 2018. Complement C3 drives autophagydependent restriction of cyto-invasive bacteria. Cell Host Microbe 23 (5), 644–652. e5. https://doi.org/10.1016/j.chom.2018.04.008. Sosoniuk, E., Vallejos, G., Kenawy, H., et al., 2014. Trypanosoma cruzi calreticulin inhibits the complement lectin pathway activation by direct interaction with LFicolin. Mol. Immunol. 60 (1), 80–85. https://doi.org/10.1016/j. molimm.2014.03.014. Sp¨ ath, G.F., Garraway, L.A., Turco, S.J., Beverley, S.M., 2003. The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc. Natl. Acad. Sci. USA 100 (16), 9536–9541. https://doi.org/ 10.1073/pnas.1530604100. Speth, C., Rambach, G., 2012. Complement attack against Aspergillus and corresponding evasion mechanisms. Interdiscip. Perspect. Infect. Dis. 2012, 463794. https://doi. org/10.1155/2012/463794. Spiller, O.B., Morgan, B.P., Tufaro, F., Devine, D.V., 1996. Altered expression of hostencoded complement regulators on human cytomegalovirus-infected cells. Eur. J. Immunol. 26 (7), 1532–1538. https://doi.org/10.1002/eji.1830260719. Sprague, E.R., Wang, C., Baker, D., Bjorkman, P.J., 2006. Crystal structure of the HSV-1 Fc receptor bound to Fc reveals a mechanism for antibody bipolar bridging. PLoS Biol. 4 (6), e148. https://doi.org/10.1371/journal.pbio.0040148. Strainic, M.G., Liu, J., Huang, D., et al., 2008. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+T cells. Immunity 28 (3), 425–435. https://doi.org/10.1016/j.immuni.2008.02.001. A.A. Nowacka et al. Immunobiology 230 (2025) 153126 19 Sülzen, H., Began, J., Dhillon, A., et al., 2023. Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction. Nat. Commun. 14 (1), 2403. https://doi.org/10.1038/s41467023-37988-7. Tam, J.C.H., Bidgood, S.R., McEwan, W.A., James, L.C., 2014. Intracellular sensing of complement C3 activates cell autonomous immunity. Science 345 (6201), 1256070. https://doi.org/10.1126/science.1256070. Tambourgi, D.V., Kipnis, T.L., da Silva, W.D., et al., 1993. A partial cDNA clone of trypomastigote decay-accelerating factor (T-DAF), a developmentally regulated complement inhibitor of Trypanosoma cruzi, has genetic and functional similarities to the human complement inhibitor DAF. Infect. Immun. 61 (9), 3656–3663. https:// doi.org/10.1128/iai.61.9.3656-3663.1993. Tambourgi, D.V., Cavinato, R.A., De Abreu, C.M., Peres, B.A., Kipnis, T.L., 1995. Detection of Trypanosoma-decay accelerating factor antibodies in mice and humans infected with Trypanosoma cruzi. Am. J. Trop. Med. Hyg. 52 (6), 516–520. https:// doi.org/10.4269/ajtmh.1995.52.516. Thieblemont, N., Haeffner-Cavaillon, N., Ledur, A., L’Age-Stehr, J., Ziegler-Heitbrock, H. W.L., Kazatchkine, M.D., 2008. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin. Exp. Immunol. 92 (1), 106–113. https://doi.org/ 10.1111/j.1365-2249.1993.tb05955.x. Tomlinson, S., Pontes de Carvalho, L.C., Vandekerckhove, F., Nussenzweig, V., 1994. Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement. J. Immunol. Baltim. Md. 1950 153 (7), 3141–3147. Touray, M.G., Seeley, D.C., Miller, L.H., 1994. Plasmodium gallinaceum: differential lysis of two developmental stages of malaria sporozoites by the alternative pathway of complement. Exp. Parasitol. 78 (3), 294–301. https://doi.org/10.1006/ expr.1994.1031. Triantafilou, M., Hughes, T.R., Morgan, B.P., Triantafilou, K., 2016. Complementing the inflammasome. Immunology 147 (2), 152–164. https://doi.org/10.1111/ imm.12556. Tsai, H.F., Washburn, R.G., Chang, Y.C., Kwon-Chung, K.J., 1997. Aspergillus fumigatus arp1 modulates conidial pigmentation and complement deposition. Mol. Microbiol. 26 (1), 175–183. https://doi.org/10.1046/j.1365-2958.1997.5681921.x. Tsai, H.F., Chang, Y.C., Washburn, R.G., Wheeler, M.H., Kwon-Chung, K.J., 1998. The developmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence. J. Bacteriol. 180 (12), 3031–3038. https:// doi.org/10.1128/JB.180.12.3031-3038.1998. Tschopp, J., Chonn, A., Hertig, S., French, L.E., 1993. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. J. Immunol. Baltim. Md. 1950 151 (4), 2159–2165. Vandendriessche, S., Cambier, S., Proost, P., Marques, P.E., 2021. Complement receptors and their role in leukocyte recruitment and phagocytosis. Front. Cell Dev. Biol. 9, 624025. https://doi.org/10.3389/fcell.2021.624025. Vanderplasschen, A., Mathew, E., Hollinshead, M., Sim, R.B., Smith, G.L., 1998. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. USA 95 (13), 7544–7549. https://doi.org/10.1073/pnas.95.13.7544. Vedamurthy, G.V., Sahoo, S., Devi, I.K., Murugavel, S., Joshi, P., 2015. The N-terminal segment of glyceraldehyde-3-phosphate dehydrogenase of Haemonchus contortus interacts with complements C1q and C3. Parasite Immunol. 37 (11), 568–578. https://doi.org/10.1111/pim.12273. Velge, P., Ouaissi, M.A., Cornette, J., Afchain, D., Capron, A., 1988. Identification and isolation of Trypanosoma cruzi trypomastigote collagen-binding proteins: possible role in cell-parasite interaction. Parasitology 97 (Pt 2), 255–268. https://doi.org/ 10.1017/s0031182000058467. Vieira, M.L., Vasconcellos, S.A., Gonçales, A.P., De Morais, Z.M., Nascimento, A.L.T.O., 2009. Plasminogen acquisition and activation at the surface of Leptospira species lead to fibronectin degradation. Infect. Immun. 77 (9), 4092–4101. https://doi.org/ 10.1128/IAI.00353-09. Vieira, M.L., Atzingen, M.V., Oliveira, T.R., et al., 2010. In vitro identification of novel plasminogen-binding receptors of the pathogen Leptospira interrogans. Bruggemann H, ed. PLoS ONE. 5 (6), e11259. https://doi.org/10.1371/journal.pone.0011259. Vimr, E.R., Kalivoda, K.A., Deszo, E.L., Steenbergen, S.M., 2004. Diversity of microbial sialic acid metabolism. Microbiol. Mol. Biol. Rev. MMBR 68 (1), 132–153. https:// doi.org/10.1128/MMBR.68.1.132-153.2004. Vogl, G., Lesiak, I., Jensen, D.B., et al., 2008. Immune evasion by acquisition of complement inhibitors: the mould Aspergillus binds both factor H and C4b binding protein. Mol. Immunol. 45 (5), 1485–1493. https://doi.org/10.1016/j. molimm.2007.08.011. Waldo, F.B., West, C.D., 1987. Quantitation of (C1INH)2 C1r-C1s complexes in glomerulonephritis as an indicator of C1 activation. Clin. Immunol. Immunopathol. 42 (2), 239–249. https://doi.org/10.1016/0090-1229(87)90011-0. Weatherly, D.B., Peng, D., Tarleton, R.L., 2016. Recombination-driven generation of the largest pathogen repository of antigen variants in the protozoan Trypanosoma cruzi. BMC Genomics 17 (1), 729. https://doi.org/10.1186/s12864-016-3037-z. West, E.E., Kemper, C., 2023. Complosome — the intracellular complement system. Nat. Rev. Nephrol. 19 (7), 426–439. https://doi.org/10.1038/s41581-023-00704-1. West, E.E., Kolev, M., Kemper, C., 2018. Complement and the regulation of T cell responses. Annu. Rev. Immunol. 36 (1), 309–338. https://doi.org/10.1146/annurevimmunol-042617-053245. Whitton, J.L., Feuer, R., 2004. Myocarditis, microbes and autoimmunity. Autoimmunity 37 (5), 375–386. https://doi.org/10.1080/08916930410001713089. Wiesner, J., Jomaa, H., Wilhelm, M., et al., 1997. Host cell factor CD59 restricts complement lysis of Plasmodium falciparum -infected erythrocytes. Eur. J. Immunol. 27 (10), 2708–2713. https://doi.org/10.1002/eji.1830271034. Wildes, D.M., Harvey, S., Costigan, C.S., et al., 2024. Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement. Pediatr. Nephrol. Berl. Ger. 39 (1), 315–324. https://doi.org/10.1007/ s00467-023-06102-w. Wilson, M.E., Pearson, R.D., 1988. Roles of CR3 and mannose receptors in the attachment and ingestion of Leishmania donovani by human mononuclear phagocytes. Infect. Immun. 56 (2), 363–369. https://doi.org/10.1128/iai.56.2.363369.1988. Wilson, R.A., Coulson, P.S., 2009. Immune effector mechanisms against schistosomiasis: looking for a chink in the parasite’s armour. Trends Parasitol. 25 (9), 423–431. https://doi.org/10.1016/j.pt.2009.05.011. Wohlgemuth, L., Stratmann, A.E.P., Münnich, F., et al., 2022. Modulation of neutrophil activity by soluble complement cleavage products-an in-depth analysis. Cells 11 (20), 3297. https://doi.org/10.3390/cells11203297. Würzner, R., 1999. Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol. Immunol. 36 (4-5), 249–260. https://doi.org/10.1016/S0161-5890(99)00049-8. Würzner, R., 2001. Modulation of complement membrane attack by local C7 synthesis. Clin. Exp. Immunol. 121 (1), 8–10. https://doi.org/10.1046/j.13652249.2000.01263.x. Wurzner, R., 2023. The role of the complement system in infectious disease: Expert opinion on future diagnostic and therapeutic potentials. Published online November, 1. https://www.selectscience.net/editorial-articles/the-role-of-the-comp lement-system-in-infectious-disease-expert-opinion-on-future-diagnost ic-and-therapeutic-potentials/?artID=58641. Würzner, R., Xu, H., Franzke, A., Schulze, M., Peters, J.H., G¨ otze, O., 1991. Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies. Immunology 74 (1), 132–138. Würzner, R., Hobart, M.J., Fernie, B.A., et al., 1995. Molecular basis of subtotal complement C6 deficiency. A carboxy-terminally truncated but functionally active C6. J. Clin. Invest. 95 (4), 1877–1883. https://doi.org/10.1172/JCI117868. Würzner, R., Platonov, A.E., Beloborodov, V.B., et al., 1996. How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion. Immunology 88 (3), 407–411. https://doi.org/10.1046/j.1365-2567.1996.d01-663.x. Xie, C.B., Jane-Wit, D., Pober, J.S., 2020. Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets. Am. J. Pathol. 190 (6), 1138–1150. https://doi.org/10.1016/j.ajpath.2020.02.006. Yadav, V.N., Pyaram, K., Mullick, J., Sahu, A., 2008. Identification of hot spots in the variola virus complement inhibitor (SPICE) for human complement regulation. J. Virol. 82 (7), 3283–3294. https://doi.org/10.1128/JVI.01935-07. Yadav, V.N., Pyaram, K., Ahmad, M., Sahu, A., 2012. Species selectivity in poxviral complement regulators is dictated by the charge reversal in the central complement control protein modules. J. Immunol. Baltim. Md. 1950 189 (3), 1431–1439. https:// doi.org/10.4049/jimmunol.1200946. Yasuda, M., Tanaka, Y., Bando, K., Sugawara, S., Mizuta, K., 2023. Lipopolysaccharide priming exacerbates anaphylatoxin C5a-induced anaphylaxis in mice. Biol. Pharm. Bull. 46 (3), 432–439. https://doi.org/10.1248/bpb.b22-00766. Yu, Y., Wang, J., Han, R., et al., 2020. Mycoplasma hyopneumoniae evades complement activation by binding to factor H via elongation factor thermo unstable (EF-Tu). Virulence 11 (1), 1059–1074. https://doi.org/10.1080/21505594.2020.1806664. Yuan, M., Wu, N.C., Zhu, X., et al., 2020. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368 (6491), 630–633. https://doi.org/10.1126/science.abb7269. Zelek, W.M., Harrison, R.A., 2023. Complement and COVID-19: Three years on, what we know, what we don’t know, and what we ought to know. Immunobiology 228 (3), 152393. https://doi.org/10.1016/j.imbio.2023.152393. Zhou, J., Feng, G., Beeson, J., et al., 2015. CD14hiCD16+monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so. BMC Med. 13 (1), 154. https://doi.org/10.1186/s12916-015-0391-7. A.A. Nowacka et al. Immunobiology 230 (2025) 153126 20